Analysis of the Ethical, Social and Legal Issues Related to the Delivery of the Prenatal Genetic Testing in Argentina by Martin, Carolina E.
  
 
 
 
 
Université de Montréal 
 
Analysis of the Ethical, Social and Legal Issues Related to the Delivery of the 
Prenatal Genetic Testing in Argentina 
 
Par 
 Carolina Estela Martin 
 
 
Programmes de bioéthique, Département de médecine sociale et préventive 
Faculté de Médecine 
 
 
Mémoire présenté à la Faculté des études supérieures 
En vue de l’obtention d’un grade 
de maîtrise (MA) en bioéthique 
 
 
Juin 2009 
 
 
 © Carolina Estela Martin, 2009 
 
 
  
 
 
 
 
 
 
 
 
 
Université de Montréal 
Faculté des études supérieures 
 
 
 
Ce mémoire intitulé : 
 
Analysis of the Ethical, Social and Legal Issues Related to the Delivery of the 
Prenatal Genetic Testing in Argentina 
 
 
Présenté par : 
Carolina Estela Martin 
 
A été évalué par un jury composé des personnes suivantes : 
 
 
Ryoa Chung, présidente-rapporteur 
Bryn Williams-Jones, directeur de recherche 
María Graciela de Ortúzar, co-directeur 
Renaldo Battista, membre du jury 
 
 
iii 
Abstract 
The introduction of new biotechnologies in any health care system is a complex 
process that is closely tied to economic, political and cultural factors and thus 
poses a host of challenging social and ethical issues. In the particular situation 
of Argentina – that is, a country characterised by significant social inequalities  
between citizens, a scarcity of resources in health care, limited access to 
needed services, and a lack of specific health policies – the introduction of new 
genetic technologies poses serious ethical and policy challenges that need 
urgent attention by policy-makers. This project examines the case of prenatal 
genetic tests in the context of the Argentinean health care system with the aim 
of illustrating how complex their introduction can be in a nation where equal 
access to health care still needs significant improvements. Attention must also 
be given to the legal restrictions and religious precepts that strongly shape the 
use of these technologies. This further highlights the necessity of developing an 
integrated framework for the process of technology assessment, in order to 
support coherent and innovative policy recommendations applicable to the 
particular Argentinean context. 
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Résumé 
L'introduction de nouvelles biotechnologies dans tout système de soins de 
santé est un processus complexe qui est étroitement lié aux facteurs 
économiques, politiques et culturels, et, par conséquent, demande de remettre 
en cause plusieurs questions sociales et éthiques. Dans la situation particulière 
de l’Argentine - c’est-à-dire: de grandes inégalités sociales entre les citoyens, la 
rareté des ressources sanitaires, l’accès limité aux services de base, l’absence 
de politiques spécifiques - l'introduction de technologies génétiques pose de 
sérieux défis qui doivent impérativement être abordés par les décideurs 
politiques. Ce projet examine le cas des tests génétiques prénataux dans le 
contexte du système de santé argentin pour illustrer comment leur introduction 
peut être complexe dans une nation où l’accès égale aux services de santé doit 
encore être amélioré. Il faut également examiner les restrictions légales et les 
préceptes religieux qui influencent l'utilisation des technologies génétiques, ce 
qui souligne la nécessite de développer un cadre de référence intégral pour le 
processus d'évaluation des technologies afin d’appuyer l’élaboration de 
recommandations pour des politiques cohérentes et novatrices applicables au 
contexte particulier de l’Argentine. 
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Resumen 
La introducción de nuevas biotecnologías en cualquier sistema de salud es un 
proceso muy complejo, el cual esta estrechamente vinculado a factores 
económicos, políticos y culturales, y por lo tanto plantea toda una serie de 
desafíos y cuestiones ético-sociales. En la situación particular de la Argentina - 
esto es: la existencia de profundas desigualdades sociales entre los 
ciudadanos, la escasez de recursos en salud, el acceso limitado a servicios 
básicos, la inexistencia de políticas específicas, etc. - la introducción de 
tecnologías genéticas plantea serios retos los cuales necesitan urgentemente 
ser abordados por los responsables de diseñar políticas. En este trabajo se 
examina el caso de las pruebas genéticas prenatales en el contexto del 
sistema de salud argentino con el ánimo de ilustrar cuán compleja puede ser su 
introducción en una nación donde el acceso igualitario a los servicios de salud 
necesita todavía ser mejorado. Asimismo, deben examinarse las restricciones 
legales y los preceptos religiosos que influyen en la utilización de las 
tecnologías genéticas, todo lo cual hace necesario el desarrollo de un marco 
integral para el proceso de evaluación de tecnologías, con la finalidad de 
elaborar recomendaciones que contribuyan al diseño de políticas coherentes e 
innovadoras, aplicables al particular contexto de la Argentina. 
 
Palabras clave 
Genética, pruebas prenatales, evaluación de tecnologías sanitarias, bioética,  
políticas, Argentina 
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CONTEXT 
A wide array of genetic technologies is becoming available in both 
developed and developing nations. This situation is the cause of growing 
concern for health policy makers, who must evaluate the utility of these and 
other health technologies for inclusion in public health programs. Ideally, these 
policy makers would have the information necessary to rationally allocate 
scarce resources, prioritise technologies, and ensure fair access to necessary 
health care services. The reality, however, is that policy makers often do not 
have such information. In Latin America, and for my purposes Argentina, 
prenatal genetic tests (PGT) are a good example of a health technology that 
poses serious social and ethical challenges for policy makers. There is growing 
public demand for access at the same time that there are ongoing debates 
about the morality of assisted reproductive technologies, and concerns about 
the fair distribution of health care resources in a developing country where 
many people lack access to even basic health care services. In this situation, I 
argue that the field of health technology assessment (HTA), through the 
integration of ethical analyses, can provide an integrated framework for 
Argentinean policy makers to better assess and balance these various 
concerns. That is, an “ethical HTA” can help to clarify the importance and utility 
of new technologies, and so play a critical role in the “effective management” of 
modern health care systems (Hofmann, 2005 a). 
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ARGENTINEAN SOCIETY: A BRIEF PORTRAIT 
 The strong European immigration that took place at the end of 19th and 
beginning of 20th Centuries has left indelible marks on Argentinean society, not 
only in terms of language (Spanish) or architecture style, but also in terms of 
culture and social values. For example, as part of the Italian legacy, family ties 
are very close and friendship is highly valued; European influences are also 
evident in Argentinean legislation (e.g., the National Civil Code was inspired by 
the French Napoleonic Code). Catholicism is still the most representative 
religion in Argentina, and the Church exercises a strong influence over civil 
society, but also over the government; until it was amended in 1994, the 
National Constitution required that the President and Vice-president be 
practicing Catholics. 
These European influences have shaped in important ways 
contemporary Argentinean society’s approach to delicate matters related to 
reproductive health, such as contraception, abortion and the use of reproductive 
technologies and prenatal tests. Yet, only 20% of the current population of more 
than 38 million (WHO, 2005) claim to be practicing Catholics, and despite the 
apparent public prominence of Catholicism in terms of expressed social and 
family values, Argentina’s birth rate – estimated in 2007 at 16.53 per 1000 (CIA 
World Fact Book, 2007) – is the lowest in Latin America. The total fertility rate 
for 2000 to 2005 was 2.4 births per woman (United Nations, 2007), thus 
following similar patterns in many European and North American countries. 
Paradoxically, there are still serious difficulties with debating these subjects in 
4 
public, even when some issues such as unsafe abortion have become a matter 
of public health concern that need to be urgently addressed; in Argentina, 
clandestine abortions are one of the most important factors implicated in 
maternal mortality (Luna, 2006; Penchaszadeh, 2009). As will be explained 
further, these kinds of paradox are reflected in the delivery of health services, 
resulting in profound inequities and inequalities, particularly with regards to 
access to sophisticated technologies such as prenatal genetic tests. 
  
THE HEALTH CARE SYSTEM 
In Argentina, the right to equal access to health care is recognised by the 
National Constitution following the 1994 reform1. Despite such recognition, 
many people still experience difficulty in accessing needed health care services; 
the economic and social inequalities present in Argentinean society are clearly 
reflected in the way that its citizens access health care, and in the manner that 
services are provided. To better illustrate the nature of such inequalities, a 
detailed description of Argentina’s intricate and complex health care system is 
necessary. 
                                                 
1In the Argentinean National Constitution, Article 42 explicitly recognises health related to 
consumers’ rights to public services; article 75 section 22 incorporates many International 
Covenants that Argentina has signed in which the access to health care is considered a 
fundamental human right. These Treaties have Constitutional authority and therefore they have 
supremacy over domestic laws: American Declaration of the Rights and Duties of Man (OAS 
1948), Universal Declaration of Human Rights (OAS 1948), American Convention on Human 
Rights. Pact of San José Costa Rica, International Pact on Economic, Social and Cultural 
Rights, International Covenant on Civil and Political Rights, Optional Protocol to the Covenant 
on Civil and Political Rights, Convention on the Prevention and Punishment of the Crime of 
Genocide Convention on the Elimination of All Forms of Racial Discrimination, Convention on 
the Elimination of All Forms of Discrimination against Women, Convention against torture and 
other cruel, inhuman or degrading, the Convention on the Rights of the Child, Declaration of 
children's rights. 
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Since its very beginning, the provision of health insurance and delivery of 
health care services in Argentina has been fragmented and heterogeneous, and 
closely related to labour unions (Belmartino, 2001). During the first period of 
immigration in the 19th Century, each community of immigrants (Spaniards, 
Italians, French, etc.) provided health care to its members through 
communitarian organizations called “mutual societies”, based on member 
solidarity and contribution to a central fund to help those in need. These 
European immigrants also brought with them ideals about the importance of 
social insurance that were in “vogue” in their home countries (Shield, 2003). So 
it was the various labour organizations (sindicatos) – metallurgy workers, 
farmers, teachers, the army, etc. – that, at the beginning of the 20th Century, 
created a system of social security for the country. Each sindicato was charged 
to collect money from its workers and employers in order to contract health 
services for their employees and their families (Shield, 2003). 
 It was only in 1943, with the creation of the Department of National 
Hygiene (today the National Health Ministry), that public health was recognized 
as specific matter for government involvement in Argentina; so a public health 
care system was created, based on the ideal of free and universal access to 
services (Tobar, 2001). Between 1945 and 1955, a strong social policy was 
implemented under Juan Peron’s first government, and access to health care 
came to be recognized as a public value and a basic civil right. An extensive 
network of public hospitals was established during the 1940s, financed through 
general taxation (Belmartino, 2001; Tobar, 2001). The social security sector 
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was also strengthened with the creation of the obras sociales which functioned 
as health insurance funds and were administered by their respective labour 
unions (sindicatos). Later, in the 1950s, a private health care sector also 
emerged and expanded greatly. The Argentine health care system thus has 
three main components: the public health sub-sector, the social security sub-
sector and the private sub-sector (Belmartino, 2001).  
 
a) The public sub-sector 
The public sub-sector is co-managed by the national, provincial and 
municipal governments. It includes universal health insurance – similar to that 
which exists in Canada – and is made up of approximately 1200 state hospitals 
and 600 medical clinics that provide a wide range of services, ranging from 
primary care (e.g., family and preventative medicine), to technologically 
complex interventions (e.g., haemodialysis and organ transplantation). This 
sub-sector is financed from general tax revenues, although funding has 
decreased dramatically in recent years due to the profound economic crises of 
20012. Public hospitals are the only facilities accessible to the lower socio-
economic classes and the unemployed, and serve the 12 million Argentines 
(approximately one third of the country’s population) who are not insured by 
                                                 
2At the end of 2001, Argentina suffered one of the worst (if not the worst) economic crises in its 
history. In January 2002 the Argentinean situation at all levels – social, political and institutional 
– was in utter disarray: the currency was devaluated by 80%, many banks closed, the 
government defaulted on its international debts, the budgets of all state areas (education, health 
care services, public infrastructure) were drastically reduced; the unemployment rate grew 
rapidly to 20.7% putting 57% of the population into poverty. For a detailed description of the 
situation see: International Monetary Fund, Executive Board Concludes 2006 Article IV 
Consultation with Argentina, Public Information Notice (PIN) No. 06/93 available at: 
http://www.imf.org/external/np/sec/pn/2006/pn0693.htm#P30_355 
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their employers (Acuña and Chudnovsky, 2002) or do not have private 
insurance. However, people insured by obras sociales (social security) and 
private health plans can also access public services for free since the public 
sub-sector is accessible to the entire Argentinean population.  
 
b) The social security sub-sector (Obras sociales) 
The social security sub-sector is composed of the obras sociales which 
play the role of health insurance funds for workers and their families. Funded by 
mandatory contributions from workers and employers, the obras have been 
controlled and administrated by the labour unions which provide health care to 
their beneficiaries: the “blue-collar workers, employees and retired persons” 
(Penchaszadeh, 2009) access health care services through their own service 
providers, but also through facilities and services contracted from private 
service providers. However, the political nature and interests of the labour 
unions, and by extension the obras, combined with a lack of transparency in 
their administration (Moyano and Escudero, 2005), led to decisions that did not 
necessarily or always promote the general welfare of their members. For 
example, the monies collected from contributors were often employed to fund 
travel for retired people or to maintain privileges of the labour unions’ leaders 
(Belmartino, 2001). 
 
8 
c) The private sub-sector 
The private sub-sector is made up of private health insurance 
organizations known as empresas de medicina pre-paga (pre-paid medicine 
companies), for-profit institutions that contract private services to cover their 
clients in exchange for a monthly fee (although some also operate their own 
facilities). But this sub-sector also includes private hospitals and physician 
associations. The pre-pagas offer a variety of private health insurance plans 
with different types of medical coverage, although some minimal services are 
compulsory (required by the state), as in the case for the obras sociales. There 
are nearly 170 private health care facilities across Argentina, although most are 
concentrated in the central part of the country. These facilities provide health 
care services to 8% of the population, that is, to those Argentineans belonging 
to the middle- and upper-income groups of the population who can afford the 
fees and prefer to pay for private services (Arce, 2003). A primary driver for the 
purchase of private insurance is that many people consider the private sub-
sector to provide higher quality care than that which is available in public 
facilities (Ucin, 2005). 
As de Ortúzar notes (2003), one of the main characteristics defining 
private health insurance – beyond the ability to pay – is a system based on risk 
stratification. Private insurance is voluntary, and the fees variable; the cost of a 
policy will vary according to similarities and differences in a person’s health 
risks. What is problematic with this private model of health insurance, is that the 
people in most need of health care are often excluded from coverage, not only 
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based on ability to pay, but also because they are considered “at too high risk” 
(de Ortúzar, 2003). 
 
Financing 
During the second half of the 20th Century, Argentina became a victim of 
successive internal economic and political crises, including the worst 
dictatorship in Argentina’s history (1976-1983)3. This turmoil resulted in 
profound institutional decadence, evidenced by inefficiency and corruption in all 
sectors of government, which was particularly noticeable in the organisation of 
the health care system and delivery of services. Since the 1960s, public health 
expenditure has been severely constrained which resulted in a failure in upkeep 
of public facilities and massive inefficiency (Shield, 2003). Simultaneously, as 
Belmartino argues (2001), the expansion of the obras sociales and the private 
sector has further deepened the inequities in access to and provision of 
services among the different sub-sectors of the health care system. 
During the 1990’s, as a part of reforms introduced into the health care 
system, the Programa Médico Obligatorio (Mandatory Medical Program, PMO)4, 
was created to ensure that all employees covered by the social security system 
received a minimum set of health benefits, including basic primary care, 
                                                 
3Between 1976 and 1983, tens of thousands of people disappeared (los desaparecidos). This 
period known as the national reorganisation process (Proceso de Reorganización Nacional) 
was characterized by political repression and murder of many people that opposed the military 
government. During those years, appalling civil and human rights violations occurred: the 
National Constitution was suspended and all democratic institutions were suppressed; the trade 
unions, political parties, professional associations and all public assemblies were prohibited. For 
more information about this subject, see for example Avery, 2004. 
4For a detailed information about this program see: República Argentina. Ministerio de Salud y 
Ambiente, (1996) Programa Médico Obligatorio available at: 
http://www.isalud.org/documentacion/PMO2.pdf. 
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secondary care (hospital stays), preventative care (e.g., pre- and post-natal 
care for mothers and children, breast cancer screening), mental health care, 
rehabilitative care, dental care, medications, palliative care, and also 
haemodialysis. This program was extended in 1997 to include family medicine 
as part of primary services (Belmartino, 2001; Shield, 2003). However, with the 
burden of the economic crisis and growing unemployment, the social security 
system lost much of its economic base: the obras sociales did not have enough 
revenue to pay for health care staff salaries or all insured health services. 
 
Interdependence of the sub-sectors 
Although each sub-sector of the health care system is funded by different 
sources and managed by different actors, they are still intimately connected. 
Thus, companies offering private health care services (either as part of pre-paid 
insurance, or direct purchase), are also some of the most important providers of 
subcontracted services for the obras sociales and the public hospitals. As 
mentioned previously, people insured by private companies can also access 
public health care services since these are open and available to the entire 
population. 
There is great diversity in the medical plans offered by the obras sociales 
and private insurance providers: the medical services delivered to the 
population are heterogeneous, and quality varies substantially depending on 
the sub-sectors, and even within them. Services are usually very good and 
waiting times short or nonexistent in the private sector; by contrast, given the 
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lack of funding in the public sector, not all necessary health care services are 
offered, they may be of lower quality (e.g., older equipment, lack of supplies), 
and there are usually very long waiting lists. This then results in an extremely 
complex and intricate system which fosters many injustices: the wealthy have 
access to double insurance – i.e., public and private insurance and services – 
that can allow advantageous selection of service providers and the jumping of 
waiting lists. For many people, including the most vulnerable, the only access to 
health care services is through the public sector, which is not always easy, 
especially for those living in the poorest and most isolated regions of the 
country.  
As already mentioned, the right to equal access to health care was 
recognised by the National Constitution in 1994; paradoxically, this occurred at 
the same time that Argentina’s government tried to reform the health care 
system by applying the neoliberal policies of the World Bank and the 
International Monetary Fund (IMF) (World Bank, 1993). These policies aimed to 
reduce state funding for public health to a set of “essential clinical services”, 
leaving the rest of medical assistance to be privately financed or covered 
through social insurance (Bertomeu, 2005; Iriart and Waitzkin, 2006). 
Successive governments failed to reverse the situation – that is, 
heterogeneity in the delivery of services, inefficiency and increasing costs – 
which worsened significantly during the economic crisis of 2001; in 2009, 
system organization and rationalization is still urgently needed. The economic 
crisis had a tremendous impact on the public health sub-sector which was 
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particularly badly hit due the convergence of many factors: the State was 
extremely slow in transferring funds to hospitals which became almost 
completely unable to provide basic services; public hospitals in many areas 
were forced to close; and physicians and nurses went unpaid for months (Iriart 
and Waitzkin, 2006; Shield, 2003). In addition, as a result of the monetary 
devaluation, the costs of medicines and technologies imported from abroad 
(e.g., diagnostic reagents, disposable materials) increased considerably 
(Cetrángolo and Devoto, 2003), making their replacement almost impossible. 
High rates of unemployment reduced contributions to the social security sector, 
and many people who had private insurance cancelled their plans because they 
could no longer afford the monthly fees. There was thus a massive transfer of 
people from others sub-sectors to the public sub-sector, which then found itself 
completely overburdened (Iriart and Waitzkin, 2006). 
In March 2002, with the health care system in almost total collapse, the 
government was compelled to declare a national sanitary emergency in order to 
ensure the provision of basic essential medical services to the entire population 
(República Argentina, Emergencia Sanitaria Nacional, Decreto no. 486/02). A 
basic basket of generic medicines was prepared (around 200) as well as a list 
of reference prices; drug prices had expanded greatly due to the monetary 
devaluation (PAHO, 2002). Importantly, the Ministry of Health also announced 
that it would be necessary to implement a formal process of technology 
evaluation in order to help rationalise decisions in health care funding and 
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delivery (República Argentina, Programa Médico Obligatorio y Evaluación de 
Tecnologías Sanitarias, Decreto no. 674/2003). 
The health care system’s diversification and lack of rationalization are 
still important challenges in need of resolution, if Argentina is to move towards a 
more equitable provision of health care services and meet the legal and ethical 
obligations enshrined in the National Constitution. The case of prenatal genetic 
testing (PGT) – whether provided through public or private health insurance – 
will serve as a focus for better understanding how to address these broader 
economic, social and ethical challenges. 
 
RESEARCH PROBLEM 
The use of genetic tests5, along with other medical genetics services 
such as genetic counselling, is spreading rapidly around the world, including to 
developing nations. In many countries – such as Canada, Australia or Cuba – 
the majority of people access genetic services through public health care 
systems, although private purchase is also an option in many jurisdictions. In 
this thesis, I focus on the case of prenatal genetic testing (PGT) and its 
introduction into the Argentinean health care system. 
Prenatal genetic testing is the class of genetic tests designed to 
determine or predict whether a fetus has (or is at risk of having) an inherited 
                                                 
5Following Williams-Jones (2002), I here define ‘genetic testing’ as “The analysis of a particular 
gene in order to provide predictive or pre-symptomatic information – usually for high penetrance 
genes – about the nature or time of disease onset; or susceptibility information – for genotypes 
of low penetrance – about the potential or risk of developing a particular disease”. This definition 
includes tests that can determine: carrier status for inherited recessive disorders (e.g.: Cystic 
fibrosis); for inherited dominant disorders (e.g.: Huntington’s disease) and x-linked disorders 
(e.g.: hemophilia) and also for some inherited adult onset disorders. 
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disorder or other genetic condition. For the most part, these tests have been 
conducted following invasive measures such as amniocentesis, although there 
are emerging and much less invasive technologies that would allow for PGT 
using maternal blood samples (identification of fetal DNA in maternal blood).  
PGT provides information that parents can use to make a decision about 
whether to continue with or terminate a pregnancy (Penchaszadeh, 2000). 
While some tests provide information about the risk of a fetus developing a 
disease later on in life (e.g., for some hereditary cancers), the more established 
and widespread use is to diagnose a condition or disorder (prenatal genetic 
diagnosis, or PGD). In addition, genetic tests (whether diagnostic or predictive) 
are characterized by varying degrees of accuracy (there may be false positive 
or false negative results) and clinical utility. As such, decisions about their 
inclusion for coverage in public health insurance programs (which genetic test 
and for whom?) necessitate both a technical or scientific evaluation, as well as 
an analysis of the ethical, policy and social implications. 
In Argentina, the integration of PGT into the public health care and social 
security sub-sectors is still quite limited, due in part to the lack of resources but 
also because of their controversial nature (Penchaszadeh, 2009). Nor are there 
explicit public policies dealing with medical genetics services, which creates 
uncertainty about who can or should access genetic testing and under what 
conditions. As Penchaszadeh notes, this is due in large part to the illegal status 
of abortion. Genetic tests are, nevertheless, widely available through private 
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health clinics, but given their high costs,6 they are beyond the means of most of 
the Argentinean population. A national census conducted in 2004 (Liascovich, 
Rozental, Barbero, Alba and Ortiz, 2005) about access to genetic services 
showed that there are also some public institutions offering genetic services, 
but due to understaffing, under-funding and uneven geographical distribution, 
many people who might benefit from these services simply do not have access. 
This situation thus raises important questions about fair access to 
appropriate genetic services. In particular, are these services (e.g., counselling, 
PGT) important enough to be covered by public health insurance? Should they 
be publicly insured in a country with major inequities in health and access to 
health care? These questions cannot, however, be answered without also 
paying attention to the serious public and policy disagreements about the 
application of genetic services (and specifically PGT) in Argentina. Given that 
the Catholic Church still has a strong influence over civil society and 
government, terminating a pregnancy remains a criminal offence; so this option 
is not available for prospective parents when they receive genetic information. 
Thus, it is necessary to also question what follow-on services (e.g., genetic 
counselling) are appropriate and/or should be available to help parents deal 
with the information resulting from genetic testing. The current situation in 
Argentina constitutes an important problem of social justice. These challenging 
                                                 
6Prices range from US$240 for Fragile X testing, to US$862 for testing for hereditary breast and 
ovarian cancer. Asociación Argentina síndrome frágil X available at: 
http://www.detodounpocotv.com/prevencion/xfragil.htm. Also, see: Asociación Médica Argentina 
available at: http://www.ama-med.org.ar/publicaciones_revistas3.asp?id=108  
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questions call, I suggest, for a deeper reflection and public discussion about the 
appropriateness of publicly funding expensive and contentious technologies. 
This thesis examines and seeks to understand the ethical rationales for 
justifying the public coverage of PGT in the socio-cultural and economic context 
of Argentina. More specifically, I hope to contribute to the emerging Latin 
American Bioethics and HTA communities by examining two subjects – the 
possibility of developing an integrated ethical HTA, and the challenges of 
evaluating PGT for inclusion in public health insurance – that have not been 
well developed in the particular context of Latin American countries. I argue that 
Argentinean policy makers currently lack the relevant and necessary tools to 
analyse the consequences of incorporating (or not) health technologies such as 
PGT into public and private health insurance programs. In presenting an 
integrated model of ethical HTA, this thesis aims to contribute to enlightened 
decision making processes about the allocation of scarce resources in health 
care in Argentina. 
 
LIMITATIONS 
The limited development of HTA – both in terms of agencies and 
procedures – in Latin America and Argentina posed important challenges to 
gathering the necessary information to conduct my study. In general, 
government agencies and public institutions – such as hospitals, laboratories 
and universities – did not have much information available about their practices, 
and web sites were often not up-to-date. Nonetheless, through a 
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comprehensive review of scholarly databases (e.g., through the Université de 
Montréal, Google Scholar, and the Humgen database), I was able to access to 
some of the key policy documents from government agencies in Argentina, 
NGOs, ethics guidelines, and academic literature about the diverse implications 
raised by genetic technologies. 
I also travelled to Argentina on two occasions (in March 2006 and then 
again in March 2007), where I met with bioethics scholars, HTA producers and 
policy-makers. In addition, I established regular email contact with several 
public and private institutions working in genetics (e.g., Centro Nacional de 
Genética Médica, CENAGEM) and HTA (e.g., Instituto de Efectividad Clínica y 
Sanitaria, IECS). Those contacts in Argentina supplied me with very helpful 
information about how things are currently being done in Argentina with regards 
to the provision of and access to prenatal genetic tests, and the integration of 
socio-ethical, legal and policy questions into the HTA process. 
Given the limitations of space and time possible for a Masters thesis, I 
chose not develop some of the complex topics closely linked to the use of PGT, 
such as patent rights and their impact on the cost of genetic tests. Nor have I 
gone into the debate about whether or not people should terminate pregnancies 
for genetic reasons, nor how follow-on services such as genetic counselling 
should be provided to support people undergoing testing. The reality is that 
even in Argentina, people are using PGT and are terminating pregnancies, and 
these raise important issues that should be addressed and publicly discussed. 
So I have limited my analysis to presenting a model for an ethical HTA and 
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showing how it would be applied to these challenging issues, in order for 
Argentina to move towards a more equitable provision of health care, and 
specifically as concerns access to genetic services for those who are in need. 
 
OUTLINE 
The thesis is structured as follows: Chapter One begins with a brief 
history of the development of health technology assessment (HTA) in the 
developed world, and then explores approaches to integrating ethical reflection 
and analyses into HTA processes, as a way to analyze and clarify the 
importance of considering PGT for coverage under public health insurance. The 
Québec Agence d’évaluation de technologies et de modes d’intervention en 
santé (AETMIS) is presented as an example of such an integrated ethical HTA, 
and the basis for a framework with which to consider the current situation in 
Argentina. In Chapter Two, I apply this framework to the case of PGT in 
Argentina. This Chapter is divided in two parts (A and B): part A is devoted to 
examining the problem of social and economic inequalities and its impact on 
access to services, while part B discusses the practical challenges for 
producing an ethical HTA that can deal with the myriad ethical, legal and social 
implications of incorporating PGT into public health care insurance. In the 
Conclusion to this thesis, I present arguments that justify the claim for equal 
access to PGT, and suggest some directions for future research. 
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CHAPTER I 
 
TOWARDS AN INTEGRATED FRAMEWORK FOR ETHICAL HTA IN 
ARGENTINA 
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INTRODUCTION 
Starting with a description of the history and development of health 
technology assessment (HTA)7, and the current state of the subject in 
Argentina, this chapter then focuses on the specific case of prenatal genetic 
tests (PGT). In Argentina, a large part of the population experiences many 
difficulties with access to health services and technologies. In addition, religious 
influences and restrictive legislation turn the application of PGT into a source of 
serious social and ethical dilemmas. In this context, the integration of ethics in 
the process of technology evaluation becomes necessary, albeit difficult to 
implement. At the end of this chapter, I present the case of the AETMIS in 
Québec, as an example to illustrate key elements for developing a preliminary 
model of ethical HTA in Argentina. 
 Implementing better HTA processes can, I suggest, contribute to more 
rational decision making and so also to more just and fair resource allocation 
decisions. It should be obvious, however, that many other actions are 
necessary in order to resolve the broader socio-political and economic 
challenges facing Argentinean society. Attention to the social determinants of 
health8 highlights the importance of social policy interventions such as poverty 
reduction, improvement of public education, enhancement of universal access 
to health and social services, control of tax evasion, etc. An ethical HTA can 
                                                 
7According to the Swiss Network for HTA, “Health Technology Assessment is the scientific 
evaluation of medical technologies regarding their effectiveness, appropriateness, efficiency as 
well as social and ethical aspects and implications”.  
8The “social determinants of health” are those social factors that affect the health of the 
population such as the socio-economic inequalities, poor education and housing, 
unemployment, etc. For more information see: WHO, 2003.  
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nonetheless help with these challenges, in so far as it enables better 
organisation and provision of essential services by providing a mechanism to 
determine priorities and so build realistic health policies adjusted to the 
particular Argentinean socio-cultural context.  
However, as will be explained below, systematized analyses of ethical 
issues are rarely performed as part of HTA processes. Producing an ethical 
HTA requires at least some knowledge about (bio)ethics matters such as ethical 
principles and justice theories that would enlighten, for example, the process of 
fair allocation of scarce resources in health care. Such knowledge would allow 
for the building of frameworks and procedures to guide ethical analyses, 
something that is lacking in the international HTA community in general. The 
issues faced by Argentinean HTA producers are very challenging, and arguably 
go beyond the tools that they have in hand. Here, I argue that Argentina’s 
Bioethics community, which has developed substantially during the last decade, 
can contribute in important ways to the production of better HTA.  
 
HISTORY & DEVELOPMENT OF HTA 
 The assessment of health technologies is not a new subject, since 
medical scientists and health administrators have for years been evaluating 
new and existing technologies; but it was not until the 1970’s that a 
systematized and empirical approach to HTA emerged, and eventually became 
both a professional practice and an academic discipline. Prior to the systematic 
use of HTA, decisions in the health policy arena were not well informed about 
diverse and important aspects (e.g., safety) of technologies. As Lehoux 
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explains (2006), analysts of health policies noted that some extremely 
expensive devices (such as the computerized tomography scanner), treatments 
and tests were promptly acquired by hospitals without the support of sufficient 
evidence about risks and benefits for patients. Policy makers lacked the 
technical knowledge and pertinent tools to analyse the consequences of 
implementing these new technologies. In 1974, the U.S. Senate Committee on 
Labour and Public Welfare requested the Office of Technology Assessment 
(OTA) to study the justifications for North American hospitals implementing 
expensive health technologies and procedures.9 The result of this inquiry was a 
series of documents, and the development of “…a new analytical tool for the 
health policy arena” (Lehoux and Blume, 2000). 
 Since the 1980’s, the interest manifested by different stakeholders (e.g., 
governments, health care managers, the pharmaceutical industry, academics, 
patient associations, and policy makers) for HTA has been growing 
considerably, especially in the developed nations. Some challenges, such as 
the rapid and widespread introduction of new technologies, their increasing 
costs (in the context of limited health care budgets) and a lack of 
standardisation in practices, plus the uncertainty provoked by as yet unknown 
effects, are just some of the reasons that have contributed to this growing 
interest in HTA (Hofmann, 2005 b; PAHO, 1998; Valencia and Manrique, 2004) 
. 
                                                 
9For a detailed discussion of the origins and development of HTA and the creation of OTA see 
for example: National Information Center on Health Services Research and Health Care 
Technology, available at: http://www.nlm.nih.gov/nichsr/hta101/ta10103.html 
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 Thus, by mid-1990, the USA, Canada and most western European 
countries had implemented diverse health technology evaluation systems 
through the creation of public and/or private agencies (ministerial commissions, 
non-governmental organisations, universities research teams, etc.). These 
groups were given the mandate to evaluate the security, effectiveness and cost-
efficacy of new biomedical technologies, but also their economic, legal and 
socio-ethical implications; in practice, however, socio-ethical analysis has been 
and is still rarely performed (Lehoux and Williams-Jones, 2007). 
In addition, regional cooperation programs, such as the EURASSES 
Program created by the European Union in 1994, were established with the aim 
of defining assessment priorities, common guidelines and evaluation methods 
for the European States10. International HTA groups were also created, most 
notably the International Society of Technology Assessment in Health Care 
(now called Health Technology Assessment International, HTAi)11 and the 
International Network of Agencies for Health Technology Assessment (INAHTA) 
that was established in 1993 and currently includes members from more than 
40 national HTA agencies. According to its institutional website, the purpose of 
INAHTA is to “provide a forum for the identification and pursuit of common 
interests to health technology” (INAHTA, 2007). INAHTA also edits a newsletter 
                                                 
10EURASSES was a research project coordinated by Prof. D. Banta and funded by European 
BIOMED Programme; the project has built a framework for the future development of HTA in 
Europe and was later continued by another project called European Cooperation on Health 
Technology Assessment (Conde Olasagasti, 1998)  
11For more information about this professional organization and its work, see: 
http://www.htai.org/ 
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with information about current trends in research on health policies, publications 
and future developments. 
Although the majority of HTA is performed in order to assess specific 
new technologies (e.g., prior to the introduction of Positron Emission 
Tomography, PET Scanners) (Nauenberg, Flood and Coyote, 2006), it can also 
be used as an approach to evaluate the performance of health care systems 
and services. For example, some Canadian provinces (notably Québec and 
British Columbia) have implemented initiatives12 to reorganise services in order 
to respond more efficiently to their populations’ health needs. In Canada, the 
restructuring of health care systems has in part been necessitated by the “aging 
population, rapid development of medical technologies and increasing costs” 
(Battista and Hodge, 1999).  
 
AN INTEGRATED FRAMEWORK? 
 According to Blancquaert and Caron (2003), the process of HTA can be 
described as a combination of two phases or stages: 1) assessment: in which 
epidemiological studies are performed, involving the collection of all available 
information (e.g., literature review, cost-effectiveness analyses) and then a 
subsequent analysis and synthesis; and 2) appraisal: in which contextualised 
studies are conducted and recommendations made (e.g., in the case of PGT, 
tests can be evaluated regarding “their utility, feasibility and acceptability” in a 
given context). As Blancquaert explain (2006), contextual analyses that are 
                                                 
12In the most important Canadian cities, notably Montréal, Toronto and Vancouver some 
hospitals are already performing their own evaluations (CHSRF, 2007) 
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broader or more comprehensive than the standard or traditional assessments 
are needed in order to produce clear and pertinent recommendations adjusted 
to the local reality. Thus, the appraisal phase aims to go beyond economic 
studies and literature reviews (e.g., about safety and risks), in order to also 
address socio-ethical questions, by taking into account the environment in 
which a technology emerges, as well as the different positions of the various 
stakeholders concerned by the use of such a technology (Blancquaert, 2006).  
 Yet despite the recognition in the HTA community of the need for 
broader evaluations that include socio-ethical issues – something that has been 
stressed since the very beginning of the field – the aforementioned appraisal 
phase is not yet performed in a systematized manner by HTA agencies. 
Furthermore, classical HTA processes usually do not result in formal 
recommendations; instead, they produce technical reports about some aspects 
of technologies (e.g., cost-effectiveness, safety) that are likely insufficient for 
decision-makers to be fully informed (Nauenberg et al. 2006). This gap between 
HTA mandate and practice has been highlighted by HTA producers and 
bioethics scholars, e.g., in a series of works published by Poiesis and Praxis in 
2004 (issue 2) (cited in Lehoux & Williams-Jones 2007). Specifically, it is 
argued that even when HTA producers recognise the importance of and need to 
address socio-ethical matters (especially regarding questions raised by the 
application of new technologies) these analyses prove difficult because of the 
lack of specialised staff and economic resources to assess, in a timely manner, 
all aspects of a technology (Gallo, 2004; van der Wilt, 2004). 
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In addition, as noted by Lehoux and Williams-Jones (2007), the absence 
of adequate frameworks and procedures to guide such ethical analyses further 
complicates the situation. As a result, the formal integration of socio-ethical 
analyses is mostly conducted by “ad-hoc advisory groups” (Faulkner 1997, cited 
in Lehoux and Blume 2000), even in jurisdictions where HTA has been 
practiced for many years. It should not be surprising then, that if integrating 
socio-ethical analyses into HTA is difficult in industrialised nations, the situation 
will be even more challenging in developing countries, such as those in Latin 
America, in which this multidisciplinary field of study is just in its earliest stages 
of development (Valencia and Manrique, 2004). 
 
HTA in Latin America  
 In 1998, a study was conducted by the Pan American Health 
Organization (PAHO) with the aim of determining the situation of HTA in “the 
Americas”. This study identified two major pitfalls for the Latin American nations 
regarding the implementation of technology evaluation procedures: 1) the 
“misunderstanding of decision-makers about the relevance of HTA in the 
development of health care systems”, and 2) the absence of specialised staff 
(PAHO, 1998). This study also determined that, as a consequence of the lack of 
evaluations, countries in Latin America were incorporating new health 
technologies into their health care systems without taking into account their own 
regional particularities, “resulting in a diffusion of the most sophisticated 
technologies in inverse relation to the populations’ health needs” (PAHO, 1998). 
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This then results in a waste of limited resources, the use of possibly 
inappropriate technologies, a population with unmet medical needs, and other 
unjust situations, subjects that will be analysed further on in this Chapter in the 
specific case of Argentina. 
 In developing countries, people often experience many difficulties 
accessing health care services, especially those of the lowest income (Peters et 
al., 2007). This situation is worsened by institutionalised inefficiencies, unequal 
resource allocation and aging infrastructures. All of these are common patterns 
in Latin America, a region where despite there being a tradition of social aid for 
the poorest sectors of society, appropriate and timely access to health care is 
almost a privilege, available only for the wealthiest. In this context, more 
inclusive health policies which have the potential to improve access to essential 
services are necessary. I will argue that a more comprehensive and ethical HTA 
would help support the development of such policies.  
  
HTA in Argentina 
 Although international organisations such as PAHO and World Health 
organization (WHO) have been working since the 1970’s to promote the 
development of HTA across Latin America – organising diverse seminars and 
encouraging collaborative studies – (PAHO, 1998) it has taken almost 30 years 
to formalise the assessment process in Argentina. Until the beginning of 2000, 
Argentinean decision makers did not recognise HTA as a tool that could help 
with the rational allocation of resources (Rubinstein, Belizán and Discaciatti, 
2004). However following the severe economic crisis that affected the country in 
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2001, the demand for HTA has been growing considerably and its role in the 
decision-making process has also increased. Argentinean policy makers have 
noted that a formal process of technology evaluation can contribute to 
transparency and efficiency in health policy decision-making processes 
(República Argentina, Programa Médico Obligatorio y Evaluación de 
Tecnologías Sanitarias, Decreto no. 674/2003). 
  Decision makers are now more aware of the relevance of HTA, and so 
the development of local HTA studies is being encouraged (Pichon Riviere, 
Augustovski and Rubinstein, 2006). Such awareness is a very positive step in 
the right direction, yet as will be further explained below, the systematised 
production of contextualised studies and formal integration of ethical issues in 
HTA is still missing in Argentina. 
Currently, one of the most active producers of HTA in Argentina is the 
Instituto de Efectividad Clínica y Sanitaria (IECS), which during the period 
2003-2006 published 117 HTA documents13; their assessments consist 
primarily of a literature review and evaluation about the quality of the available 
scientific evidence. The IECS does not, however, conduct socio-ethical 
assessments, nor does it work in collaboration with other institutions or 
                                                 
13In 2002, the Instituto de Efectividad Clínica y Sanitaria (IECS), “the main HTA agency in 
Argentina”, was created as “an independent and non-profit organisation…in order to contribute 
to improve the efficiency, the equity, the quality and sustainability of the health policies and 
services”. According to the institutional website, its staff includes professionals from multiple 
disciplines such as physicians and social scientists, who are engaged in research and other 
academic activities. The Institute offers technical support to public and private institutions as 
well as non-governmental organisations in areas such as evaluation of health innovations, 
economic assessments, research methodologies, “data analysis and validation of 
questionnaires”. The principal aim of this support is to orient the use of appropriate technologies 
and decrease unnecessary expenditures. The Institute also coordinates the Ibero-American 
Cochrane Network, promoting systematic reviews of health interventions which are published in 
the Cochrane Library with the aim to improve the production of local scientific reviews. See: 
www.iecs.org.ar 
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professionals performing analyses about those matters. Its technical reports, 
albeit very helpful, only provide decision makers with information about specific 
(partial) aspects of technologies, such as costs and efficacy, which is arguably 
insufficient to enable the development of comprehensive and effective health 
policies14. Similarly, evaluations by the Comision Nacional Salud, Ciencia y 
Tecnologia (National Commission on Health, Science and Technology) – 
created by the Health Ministry in 2006 with the aim of institutionalizing HTA into 
the health care system and promoting the use of scientific evidence in the 
health policy decision making15 – consist basically of literature reviews and 
consultation with experts; the resulting short reports focus on economic 
information, e.g., about cost-effectiveness, but do not include contextualised 
studies. 
One point that deserves particular attention is the fact that the 
documents resulting from HTA producers in Argentina are in general technical 
reports about the “effectiveness, safety and cost-effectiveness” of particular 
technologies; given the lack of the appraisal phase, these reports do not include 
formal recommendations (Personal communication, Buenos Aires, 7 March 
2007). For instance, in a report produced by IECS in 2003 about prenatal 
diagnosis and genetic studies, it was concluded that given the criminal status of 
abortion in Argentina, the financing and coverage of such tests can be 
                                                 
14It is interesting to note that the IECS is the only Argentinean institution (and one of only a few 
in Latin America) affiliated with the international network INAHTA. As such, the IECS is directly 
linked with the international HTA community, which should facilitate the exchange of ideas, 
methodologies and reporting models, which could be adapted to the local context. This 
relationship provides precious opportunities for collaboration and shared learning to help 
improve and enlarge the production of HTA in Argentina. 
15See: República Argentina Ministerio de Salud y Ambiente. Comisión Nacional Salud, Ciencia 
y Tecnología, available at:  http://www.saludinvestiga.org.ar/ets-solicitud.asp  
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controversial. Thus invasive procedures, such as amniocentesis, cannot be 
indicated although they can be suggested (IECS, 2003). These types of 
conclusions (i.e., not indicated but suggested), without formal 
recommendations, can create uncertainty and ambiguity for the diverse actors 
involved (e.g., parents, physicians, other health care professionals, policy 
makers); without clear guidance, these actors will be hard pressed to make well 
informed decisions in what are very delicate situations. I argue that formal and 
comprehensive recommendations from HTA producers in Argentina are needed 
to improve efficiency and quality of services and to sustain coherent health 
policies and guidelines pertinent to the local context. Such recommendations 
necessitate enlarging the HTA process, that is, implementing the 
aforementioned appraisal phase as an integral part of HTA. 
 As has been mentioned previously, taking into account the environment 
in which a technology emerges, as well as the different positions of the various 
stakeholders concerned by the use of a given technology is needed to 
determine its appropriateness, utility and acceptability. Pursuing an agenda of 
inclusiveness and equal access to health services requires addressing many 
other factors besides clinical effects and cost-effectiveness. Contextualising the 
evaluation process would, in the case of PGT for example, allow HTA 
producers to make explicit the socio-ethical and legal concerns associated with 
access to PGT in its particular socio-cultural context. Specifically, in the 
Argentinean context, attention would need to be given to the injustices that 
arise from inequitable access to PGT (and other health care services) and its 
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impact on equality of opportunities (Daniels, 1985), as well as concerns related 
to the provision of testing, such as informed consent, confidentiality, 
discrimination, and how to deal with the resulting information (these issues will 
be examined in Chapter Two). 
 
HTA in Québec: Lessons to be learned 
 In Québec, HTA is performed by the Agence d’évaluation des 
technologies et des modes d’intervention en santé (AETMIS), which was 
created in 2000 to replace the Conseil d’évaluation des technologies de la 
santé16. AETMIS is an independent organisation but directly linked to the 
Ministry of Health and Social Services of Québec (Ministère de la santé et des 
services sociaux, MSSS), both working in collaboration and according to a 
“national strategy”. AETMIS’ goal is to support and counsel health decision 
makers in the development of scientific policy for the Québec government. 
AETMIS is strongly engaged in the promotion of evaluation, knowledge 
translation, teaching and “outreach activities” (AETMIS, 2008), similar to other 
Canadian HTA agencies and institutions in developed nations. 
    The most important evaluation requests to AETMIS come from the 
MSSS and the major Quebec hospitals, as well as other institutions or 
associations working in the health field. To start, a feasibility assessment is 
conducted in order to decide whether to proceed (or not) with a particular 
evaluation. Each assessment begins with an exhaustive literature review where 
                                                 
16For more information about the creation of the AETMIS see: décret 855-2000 from Québec 
Government (28 June 2000)  
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the pertinent information is assessed through meta-analyses, evaluating diverse 
parameters, including: cost, efficiency and security aspects, as well as ethical, 
legal and social repercussions (appraisal). If necessary, external expert advice 
is requested. A preliminary report is submitted to the AETMIS board, who give 
final approval (after corrections). Then, the report is communicated to those 
who commissioned the assessment, and finally it is made publicly available on 
the AETMIS website, among other venues. 
 AETMIS performs comprehensive analyses (assessment and appraisal), 
and so include, for example, the use of statistics, medical files and other 
scientific information – including ethical, social, economic and legal factors – 
about the Québec population (Blancquaert, 2006). Each evaluation results in a 
report that formulates pragmatic policy “recommendations directly applicable to 
the Québec health care system” (AETMIS, 2008). For example, in 2003, 
AETMIS produced a report about prenatal screening for Down syndrome during 
the first-trimester. After evaluating diverse parameters, the report concluded 
that even when the screening modalities were effective, more research was still 
needed before implementing “wide-scale first-trimester screening in Québec” 
(AETMIS, 2003).17 
  Even though it could be argued that the model of AETMIS is not perfect 
and the process of the contextualised HTA has limitations – for example, the 
evaluation’s methods are constantly evolving making it necessary to adapt them 
to the specific situation and technology – coherence, scientific rigour and at 
                                                 
17In January 2009, the Québec Commissaire à la santé et au bien-être (MSSS) published a 
report recommending the introduction of population screening for Down Syndrome 
(Commissaire à la santé et au bien-être, 2009). 
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least some degree of organisation are present in their works. What is 
particularly interesting for our purposes is the fact that AETMIS is one of the few 
agencies in Canada or internationally to have a research team working on 
evaluations of genetics technologies (a specific unit was created in 1996); 
further, AETMIS is one of the few to integrate ethical analyses, in a 
systematised manner, into their assessments.  
The ethical implications of a technology are analysed within Québec’s 
socio-cultural, economic and political context. Different methods are employed 
to achieve this integration: for instance, focus groups with stakeholders or 
inquiries to different actors (who are concerned by a given technology) 
depending on the particular circumstances of each evaluation. At this point, it is 
necessary to recognize the strong influence exerted by the various stakeholders 
involved in implementing such innovations in a given context (e.g., technology 
designers, health administrators, physicians, patient groups) as well as the 
existence of diverse perceptions, interests and expectations that each may 
have about the same technology. Considering these factors and integrating 
them as part of the HTA process allows the AETMIS evaluators to obtain more 
accurate information about the utility, feasibility and acceptability of a 
technology in the particular context of Québec. 
 
 CRITICAL CONCLUSIONS ABOUT AN INTEGRATED FRAMEWORK 
 As Blancquaert explains (2006), the analysis of the social context in 
which a technology is to be implemented “can change how one frames the 
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question and what evidence is collected”, and this can have an impact on the 
recommendations formulated. In the case of Argentina, as in other developing 
countries, the government does not consider genetic testing as a priority for the 
public health care system (Sommer, 2008); prenatal genetic tests are provided 
mostly by private institutions and thus are accessible only for the wealthiest. But 
there may be situations in which genetic tests are appropriate (e.g., for people 
belonging to at risk groups) and justifiable in relation to other important health 
needs. Yet without a comprehensive HTA process that takes such issues into 
consideration, policy makers will be unable to rationally defend their choices 
(e.g., to not include PGT in public health insurance). The development of an 
integrated framework for an ethical HTA and its application to PGT can thus 
serve to clarify the pertinence of PGT and justify (or repudiate) the claims for 
broader inclusion and equal access in the Argentinean health care system.  
To produce contextualised studies, it is obvious that substantial human 
and material resources are needed; but so to is an awareness on the part of 
HTA producers of the importance of enlarging their studies beyond simply an 
analysis of clinical and economic considerations, to include ethical and social 
issues in order to make more accurate and pertinent recommendations. 
Unfortunately, chronic understaffing and a lack of sufficient financial resources 
at HTA agencies is a major part of the problem, although it can in some places 
be overcome by re-allocating local resources; more important, however, is 
developing a willingness on the part of HTA agencies to engage in broader 
analyses.  
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The development of adequate frameworks to assess socio-ethical issues 
remains an important challenge, because as Lehoux and Williams-Jones argue 
(2007), “individual, clinical, managerial, economic, commercial, political and 
social perspectives are concurrently active in the development of new medical 
technologies and the associated values and expectations”. PGT, as with other 
technologies, is designed with the aim of providing certain information that is 
valuable for various decision makers (Lehoux, 2006); but its application 
necessarily brings in other norms and values (e.g., ethical, cultural, spiritual) 
that directly impact how a technology will be accepted (or not) and used in a 
given society. Addressing the complexity of these issues – even with an 
integrated framework that seeks to facilitate the work of HTA producers – will 
remain a significant challenge. 
However, I argue that important progress can be made if HTA producers 
in Argentina begin to integrate the aforementioned appraisal phase as an 
integral part of their HTA processes. A contextual analysis “implies a good 
understanding of the real world implications of the introduction, dissemination, 
and use of new technologies for a variety of stakeholders” (Blancquaert, 2006). 
The capacity to conduct such contextual analyses will necessitate important 
efforts in education about the ethical issues related to health care and genetic 
technologies. HTA producers should, for example, reflect on and assess the 
possible consequences of not considering sensitive issues. For example, the 
growing commercialization of genetic tests can lead to an early introduction into 
the market of services that physicians are not yet prepared to handle, and 
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provide information to patients and third parties which can have serious legal 
consequences, such as discrimination, or even malpractice suits in the context 
of “wrongful life” claims (Andrews, 1992). Similarly, the issue of patent 
protection may mean that some genetic tests are simply too costly to be 
considered for inclusion in public health insurance programs in developing 
countries like Argentina (de Ortúzar, 2004). 
In practice, integrating contextualised studies and ethical analysis into 
HTA processes will require, amongst others, the development of strategic 
partnerships between diverse spheres in “academia, practice and policy” 
(Blancquaert, 2006). In Argentina, a recent report from the aforementioned 
Comisión Nacional Salud, Ciencia y Tecnología (2008) shows that those 
researchers working on human genetics and its clinical applications are 
disconnected from decisions about the provision of health services. Better 
collaboration with the medical genetics community is needed, as well as more 
fluid dialogue between practitioners and policy makers, to avoid any 
misunderstandings. For instance, in Argentina, the field of genetics is still 
closely associated in the public mind with eugenic practices, and this is 
arguably one of the principal reasons why PGT has not been included in public 
services (Comisión Nacional Salud, Ciencia y Tecnología, 2008; Kaminker, 
2006; Penchaszadeh, 2009). Promoting dialogue among the different 
stakeholders would help enormously to eliminate such misperceptions and 
misinformation. 
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To address the complex social, ethical and economic challenges raised 
by technologies such as PGT, the integration of interdisciplinary teams is 
needed. Here, I suggest (and develop the argument more fully in Chapter Two), 
there is room for the participation of local Bioethics scholars who have been 
studying the numerous challenges raised by genetic technologies, but who 
have to date not been involved in HTA processes. These scholars can help to 
integrate the multiples perspectives of diverse stakeholders in the appraisal 
process, and stimulate dialogue between the different actors; they could also be 
instrumental in helping HTA producers and decision makers think more 
reflexively about their own values, as well as issues of fairness and equity, 
when considering who should have access to PGT.  
 A promising strategy would be to start with a small scale pilot project at a 
public or private institution in which bioethicists are employed, to develop the 
aforementioned appraisal phase of the HTA process. In collaboration with HTA 
experts, bioethics scholars could help gather the social and scientific 
information already available about PGT in Argentina. But they could also go a 
step further by consulting with key stakeholders: for example, scholars could 
interview physicians working in public hospitals in which genetic testing is 
provided in order to document existing selection criterion (if any); conduct focus 
groups with patients in need of PGT to learn about their concerns; or survey 
genetics laboratories to know what kinds of tests are in most demand. Finally, 
as seen in the case of AETMIS, the dissemination of study findings is an 
important part of the HTA process. So in the context of the proposed pilot study, 
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research results that enlighten other aspects of technologies – besides 
economic and clinical considerations – could be a way to move the issue of 
prenatal genetic tests onto the political agenda in Argentina. A survey 
conducted between 2006 and 2007 by the IECS, which sought to measure the 
impact of HTA reports in decision making, showed that in Argentina such 
reports are mainly employed (76%) to define health policies regarding the 
coverage of  health technologies (IECS, 2008). It is not unrealistic, then, to think 
that with a more comprehensive, integrated ethical HTA process, PGT could 
also be evaluated for inclusion (or not) in the public health care system. 
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CHAPTER II 
 
APPLICATION OF THE INTEGRATED FRAMEWORK TO PGT IN 
ARGENTINA 
40 
 
INTRODUCTION 
This Chapter explores how an integrated ethical HTA framework could 
be applied to an evaluation of prenatal genetic testing in Argentina. Divided into 
two parts, Part A sets the background context to genetic service provision, 
describes the socio-economic inequalities present in Argentinean society and 
its impact on equality in access to services and technologies, and concludes 
with an exploration of the major cultural, religious and political factors that make 
the PGT such a contentious subject. Part B examines some practical (e.g., 
institutional and structural) challenges for producing an ethical HTA that can 
deal with the myriad ethical, legal and social implications of implementing PGT 
into public health care insurance in Argentina, and concludes with some 
recommendations. 
 
PART A - SOCIO-ECONOMIC INEQUALITIES AND THE PROVISION OF GENETIC 
SERVICES IN ARGENTINA 
Genetic Services and Prenatal Tests: Evolution and Current Situation  
Although in most Latin American countries genetic services and genetic 
testing have only had limited uptake or integration into health care systems 
(e.g., because they are too costly), in countries such as Argentina and Brazil 
the medical application of prenatal genetics tests has become quite 
widespread. Yet even in these countries, and for our purposes Argentina, the 
integration of genetic services into the public health care system is still quite 
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limited, due in part to a lack of resources but also because of its controversial 
nature (Penchaszadeh, 2009). 
 Genetic services began to develop in Argentina during the 1960s, when 
a medical genetics section was opened at the Academia Nacional de Medicina 
(National Academy of Medicine). In 1969, the Sociedad Argentina de Genética 
(the Argentina Genetics Society) was created as a civil non-profit association 
with the purpose of gathering genetics researchers and establishing links with 
foreign institutions (http://www.sag.org.ar/). Some years later, the Centro 
Nacional de Genética Médica (CENAGEM, National Centre of Medical 
Genetics) opened its doors with the aim of conducting genetics research, 
providing teaching and training in medical genetics, and offering genetic 
services to the public (http://www.anlis.gov.ar/CeNaGeM/CeNaGeM.htm). 
During the 1980’s, a medical genetics department was opened at the Garrahan 
pediatric hospital, which is currently the main referral centre for complex 
pathologies for all of Latin America (Pechaszadeh, 1998). The incidence of 
congenital disorders and genetic anomalies in Argentina are similar to those in 
industrialised nations, constituting the second cause (27%) of infant mortality in 
Argentina in children younger than 1 year old; the mortality rate is 12.9 per 
1,000 live births (Comisión Nacional Salud, Ciencia y Tecnología, 2008; 
Penchaszadeh, 2009) .  
 At present, in most major cities – such as Buenos Aires, Cordoba and 
Mendoza – public hospitals and universities operate genetics departments and 
specialized laboratories (around 50 across the country) that perform medical 
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genetic assessments such as cytogenetic, molecular biology and biochemical 
testing to detect birth defects and genetic disorders. These facilities have 
infrastructure and communication networks that allow them to be connected 
and informed about the latest technical and scientific developments in the field. 
As is the case in most developed nations, a wide range of genetic services are 
available in Argentina, ranging from preconception to adult care18. For instance, 
it is possible to test prenatally for disorders such as Fragile X, Down syndrome, 
and neural tube defects as well as a number of monogenic diseases such as 
cystic fibrosis, thalassemia, or Duchenne muscular dystrophy among others. 
 Today, Argentina has approximately 80 medical professionals 
specialised in human genetics, a ratio of 1.77 physicians with formal genetics 
training per million inhabitants (Liascovich et al., 2006), which is similar to other 
regional countries although much less than in Europe, where the ratio is 2.7 per 
million inhabitants; as Penchaszadeh argues (2009), “understaffing” is one of 
the reasons limiting access to genetic services in Argentina. In addition, the 
absence of government policies dealing with genetic services creates 
uncertainty about who can or should access genetic testing and under what 
conditions. 
 What is interesting, for our purposes, is that despite the existence of  
public facilities, many institutions providing genetic services in Argentina are 
private centres (more than 100). Due to their private sources of revenue (and 
the chronic under-funding of public institutions), the private clinics have the 
                                                 
18Personal communication, by e-mail, with Argentinean physicians working in the genetics field 
in public hospitals and private centres (during 2006-2008) 
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capacity to incorporate new technologies faster than public facilities. Thus, 
these private centres are able to apply the same techniques as those used in 
industrialised countries, such as amniocentesis and Fluorescence in Situ 
Hybridization (FISH) for genetic testing of embryos19. The fees that these 
private centres charge are paid directly by patients, even if they have private 
health insurance, as most insurance plans do not cover genetic tests20. As 
such, they are a privilege for a wealthy minority: given the high costs of these 
technologies (in large part due to issues of patents), genetic tests and 
especially PGT (whose application is quite limited at a public level) are beyond 
the means of the vast majority of the Argentinean population, who already 
experience serious difficulties accessing services in public health facilities.  
 Beyond the impact of cost on access to genetic services and the 
aforementioned understaffing of public institutions, another important factor is 
the uneven geographical distribution of centres specialised in genetic medicine. 
In 2004, a nation-wide survey of medical genetic services was conducted with 
the aim of identifying resources, as well as diagnostic procedures and services 
used by patients. This survey, conducted by the aforementioned Centro 
Nacional de Genética Médica (National Centre of Medical Genetics) in 
collaboration with the Centro de Investigaciones Epidemiológicas de la 
Academia Nacional de Medicina (Epidemiological Investigation Centre of the 
                                                 
19The different diagnostic procedures and tests already available in Argentina are listed in the 
web site of some private institutions. For example: Primagen Diagnósticos Genéticos available 
at: http://www.primagen.com.ar/diagnosticosprenatales.php 
20The costs of genetic studies can be quite expensive for Argentineans, although they would be 
considered very affordable for people living in developed countries. For example, 
amniocenteses costs around US$100, while the subsequent genetic tests, which will vary 
depending on the pathology, range from US$240 for Fragile X (or the Martin & Bell’s Syndrome) 
to US$862 for BRCA testing for hereditary breast and ovarian cancer. 
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National Academy of Medicine) identified a total of 134 facilities, 50 of which 
were public centres, with most (70%) concentrated in the central part of the 
nation, especially in the province and city of Buenos Aires; the survey also 
determined that almost the half of the country's 23 provinces had no public 
medical genetics services (Liascovich et al., 2006). 
 With respect to the diagnostic procedures offered, significant variability 
was detected between public facilities; while many centres performed clinical 
and cytogenetic diagnoses, only a few ones (6, all of them located in the central 
part of the country) also conducted molecular and prenatal diagnoses; 44 
centres delivered services to 50-150 people per month, and 6 other institutions 
assisted more than 150 patients per month (Liascovich et al., 2006). Thus, 
people living in the Capital City and the province of Buenos Aires are the most 
favoured regarding access to genetic services while inhabitants of Argentina’s 
northern (the poorest region) and southern extremes have virtually no access to 
such services. It should be noted, however, that this concentration of medical 
facilities is not so different from that occurring in other countries, such as 
Canada, where there are no genetic services available outside the major 
metropolitan areas. Yet unlike Argentina, in Canada there exist mechanisms to 
help plan and coordinate service provision in areas without specialised genetics 
centres (e.g., genetic testing for residents of the Yukon is provided by centres in 
British Columbia)21.  
                                                 
21For a detailed list of genetic testing delivered in the provinces and territories of Canada see:  
CORD, 2008.  
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It is noteworthy that even when prenatal care is included within the 
Mandatory Medical Program (Programa Médico Obligatorio, PMO), and 
ultrasound is practiced routinely in Argentina, the development of prenatal 
genetic diagnosis has encountered many pitfalls in the public and social 
security sub-sectors. There are neither explicit public policies dealing with 
medical genetics, nor any regulations about genetic testing and this – as 
Penchaszadeh notes – is due in large part to the illegal status of abortion. By 
contrast, as mentioned previously, prenatal genetic tests are quickly 
incorporated in the private health care sub-sector and easily available for those 
who can afford them (Penchaszadeh, 2009; Sommer, 2008). 
 
Socio-Economic Inequalities and (Un)equal Access 
In Argentina, we find a fairly small and privileged portion of the 
population accessing, through private health insurance, the most sophisticated 
technologies and health services in a timely fashion, while the vast majority of 
citizens experience many difficulties accessing even primary health care. Such 
inequity in the access to health care services in general, is even more apparent 
in the case of specialised services, such as medical genetics. This inequity 
might be less problematic in countries where the population has equal 
opportunities to access needed medical services; but in the case of Argentina, 
where millions of people face many obstacles to having their health needs 
satisfied the uneven delivery of genetic services and its related technologies 
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arguably worsens existing inequalities, and undermines equality of opportunity, 
something that in a democracy every citizen should have. 
  In a developing country such as Argentina, unequal access to health 
care is a reality, but is nonetheless ethically unacceptable. Argentina is a social 
democracy that aspires to be a just society, and has even gone so far as to 
recognise in its Constitution a right to health care. The standard of access to 
health care should thus be determined by medical need, and not by capacity to 
pay. One way to understand this issue is to reflect on John Rawls’ principle of 
equality of opportunity (1971), and its application by Norman Daniels (2001) to 
the case of health care resource allocation and policy making. This principle is 
arguably an important philosophical foundation of a right to health and health 
care.22  
As de Ortúzar notes (2004), Daniels relates health with opportunities 
through the concepts of “normal species functioning” and a “normal range of 
opportunities”. Daniels describes health needs as basic goods required to 
“maintain or restore normal functioning between members of the same species” 
(Daniels, 1981). Disease becomes then a pitfall to the normal function of a 
person that reduces the aforementioned range of opportunities to self 
realization and social participation so fundamental to democratic society; 
“Protecting normal functioning contributes to protecting opportunity” (Daniels, 
                                                 
22There are important differences between Rawls’ and Daniels’ conceptions of “equal 
opportunity”. Rawls does not justify equal access to health care, but to be entitled to the 
opportunity: he supposes that all citizens are normal and then he limits the application of this 
principle to positions, jobs and careers. While for Daniels health care is important because of its 
impact on opportunity, it means that the important fact is the opportunity itself, which is 
determined by social factors; acting to promote social justice (e.g., improving socio-economic 
inequalities) is critical to achieve equality in health care. Then, access to health care is a social 
responsibility because limited access impacts directly on the “normal range of opportunities”. 
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2001). Furthermore, as Williams-Jones and Burgess (2004) note, one of the 
goals of health care is to compensate those people who are below the level of 
“normal functioning”. When unmet health (and other) needs decrease normal 
functioning, and thus the normal opportunities available to an individual, then 
they should be considered priority needs that the health care system must work 
to restore, improve or compensate to ensure equality of opportunity. According 
to this, all citizens should have access to needed health (and social) services, 
because health is essential to the pursuit of individual life goals; in a pluralistic 
liberal democracy, equality of opportunity becomes a fundamental part of a just 
society. 
Following Daniels (2001), I argue that matters concerning the entire 
society, such as health and health care – factors that are seriously affected by 
socioeconomic inequalities – necessitate public participation and social 
cooperation. In a democratic society such as Argentina, just access to health 
care (and other social) services is needed to enhance the possibilities of all 
citizens to fully participate and co-operate in social life. The State, as part of its 
duty to protect its citizens, arguably has a duty to ensure the same standard of 
health for all, not just because health is a basic right but because it is a 
condition that empowers people to exercise other rights and responsibilities 
necessary to the achievement of personal goals but also to the progressive 
development of any country. 
The persistence of unequal access to genetic services can have 
negative repercussions on society by further exacerbating the marginalisation of 
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those who are in need and cannot afford private services, or do not have the 
chance to live in a region where a public facility is located. As Rivera López 
states (2002), this affects the “the social basis of cooperation”. That is, those 
who can and prefer to purchase private services, such as PGT, will have better 
health standards than the less affluent; this arguably contributes to a loss of 
cooperation and social solidarity with the rest of society, potentially further 
entrenching negative social behaviours such as tax avoidance (which is 
rampant in Argentina) that continue to undermine the funding of public health 
and social services.  
It is also plausible that genetic tests – including PGT – can contribute to 
individual health and thus also to equality of opportunity (Williams-Jones and 
Burgess, 2004). At this point, however, it is necessary to make a distinction 
between the medical uses of genetic testing in the public health care sector, 
from its commercial and/or non-medical (or non-essential) use, usually 
pressured by market forces. In the first case, the application of PGT can 
respond to important medical needs, that is, serious genetic conditions for 
which the identification, prevention, or treatment can improve the quality of life 
of affected people. In the second case, one such application would be to satisfy 
desires or preferences that are not considered medically necessary (de Ortúzar, 
2004). While it may be hard to neatly distinguish between health needs and 
desires or preferences, the fact is that health care systems can and do set 
criteria to prioritize access to health care services. It is thus all the more 
important that such distinctions be based on rational and transparent 
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arguments, the data for which should come from sustained ethical reflection, 
i.e., part of ethical HTA processes (Williams-Jones and Burgess, 2004).  
Argentina already posses some prestigious medical facilities (e.g., the 
previously mentioned Garraham pediatric hospital is a public institution) where 
genetic services are provided. In an attempt to better organise the provision of 
genetic services and to reduce inequalities in access, Argentina’s Ministry of 
Health announced in 2005 that there was a need to develop specific policies 
and regulations regarding the application of genetic technologies and their use 
to improve public health (República Argentina, Resolución ministerial no. 
149/2005).  
The government also noted that given the state of development that 
medical genetics has reached in recent years, and its impact on public health 
(i.e., a growing number of genetic anomalies are preventable or treatable if 
detected early), there was need for a detailed framework to guide research, 
diagnosis and treatment in the field of medical genetics (República Argentina, 
Resolución no. 149/2005). In a recent report by the aforementioned National 
Commission on Health, Science and Technology, it is stated that some recent 
indicators of epidemiological transition (e.g., infant mortality rate) mean that 
birth defects and monogenic diseases are becoming a major health problem in 
Argentina (República Argentina, Foro de investigación en Salud, 2008). So a 
government initiative to develop health policies and directives regarding genetic 
testing is a very positive step in the right direction; it might even be seen as a 
demonstration of a willingness to consider, in the near future, the broader public 
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provision of genetic services, including PGT (although it is probably still to early 
to predict the impact of this good will).  
In a country such as Argentina, where there are tremendous social 
inequalities23, public debate about what is important for coverage in public 
health insurance is essential. Such participation is necessary not only to provide 
guiding values and to make explicit what services and technologies the society 
considers acceptable and reasonable, but also to clarify the health needs of the 
population as a whole and not simply the desires or preferences of those who 
can afford to pay for services. Such debate should be encouraged in order to 
determine how significant or important PGT is when considered within the wide 
spectrum of health care services necessary for Argentinean society to be 
healthy, productive and just.  
 
Cultural, Religious and Political Factors 
Beyond the different economic, material or physical obstacles that 
people face in accessing genetic services (e.g., socio-economic inequalities, 
the complex structure of health care system, and a lack of services in some 
regions), it is also necessary to examine some of the cultural, religious and 
political factors particular to the Argentinean context. In particular, I argue that 
more attention must be paid to the (apparent) strong influence that the Catholic 
Church exercises over government and civil society, most evident in legislation 
                                                 
23To better illustrate these inequities, it is enough to note that until 2001, per capita income in 
Buenos Aires province – the county’s richest one – was US$21,000, while in Formosa – the 
north-eastern and one of the poorest provinces – per capita income was only US$3,700. 
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prohibiting access to abortion24. For instance, regarding modern reproductive 
technologies – a subject closely linked to PGT – Latin American law-makers 
“have received specific mandates from the Vatican” (Zegers-Hoschschild, 1999) 
stating that since, from the moment of conception, the right to life is inviolable, 
the “manipulation and research” on the embryo and its “voluntary disposal is 
immoral”25. This ecclesiastical position, added to already restrictive legislation, 
poses a number of delicate ethical dilemmas as well as raising legal issues 
about the application of prenatal testing and the utility of the resulting 
information, making the applicability of these technologies controversial. 
In Argentina, prenatal diagnosis is one of the ethically most problematic 
applications of genetic technologies, because in some cases it may lead to 
selective abortion which is a criminal offence. Thus when a severe condition 
(which cannot be modified) is detected in the foetus and the parents do not 
desire to continue the pregnancy, they are placed in a very delicate situation. 
Who should make a decision? If it is assumed that the future parents will 
support the consequences of such decision, who can evaluate (better than 
themselves) if they will be able or not to parent a handicapped child? (Chaplin, 
Schweitzer, and Perkoulidis, 2005). How are medical professionals and parents 
to deal with the information obtained from those tests? Will there be a real 
benefit to using such a technology, and if so, for whom? And who decides who 
                                                 
24The Argentinean Criminal Code (Código Penal) establishes in articles 85, 86, 87 and 88 the 
illegality of abortion except in the case of severe risk for the mother’s life and in the case of rape 
but only when the woman raped is mentally disabled. Even in these situations for which the 
abortion is accepted, physicians usually request judges for authorization to proceed because of 
their fear for law suits. 
25For more information about those ecclesiastical mandates see: Ciudad del Vaticano (1987) 
Congregación para la Doctrina y la Fe, Instrucción sobre el Respeto a la Vida Humana 
Naciente y la Dignidad de la Procreación cited in Zegers- Hoschschild (1999). 
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should have access? These questions need to be addressed and discussed by 
decision makers if the government aims to improve access and plans to 
consider funding publicly genetic services, including diagnosis and treatments.  
Providing PGT to the broader public opens new possibilities and choices, 
and can create both personal and professional ambiguity. PGT can allow 
people to make informed and autonomous reproductive decisions, but testing 
may also engender psychological and social risks for some people, particularly 
if a severe disorder is detected. It is necessary to recognise that PGT is an 
informational tool and not a solution in itself. How are prospective parents to 
deal with a wealth of genetic information that they many not comprehend? And 
what are they to do with such information, given that the possibility to terminate 
the pregnancy, should they desire, is not available because abortion is a 
criminal offence in Argentina? 
Is it realistic to think that all people undergoing testing do so only 
because they want to be prepared to parent a handicapped child? If not, should 
policy makers acknowledge that couples will access PGT and then procure a 
clandestine abortion in the event of a detected genetic condition (which is 
currently the case in Argentina) (Penchaszadeh, 2009), or travel abroad to 
those jurisdictions where abortion is not criminalised? In societies where there 
is an important percentage of the population living below the poverty line, as in 
Argentina, many citizens will not have the means to obtain safe clandestine 
abortions; then, women are forced to use more risky methods.  
53 
 Although there are no official statistics available in Argentina, there is 
some recent data showing that an important percentage of parents who have 
gone through genetic testing would consider the possibility of an abortion if 
serious anomalies are found in the foetus, even when this would imply 
assuming all the risks of a clandestine abortion (Gadow et al., 2006). Assuming 
that many people will experience serious difficulties in making the decision to 
terminate a pregnancy, the illegality of abortion simply worsens matters. 
Discussion of this subject should no longer be postponed in Argentina. The fact 
of the matter is that clandestine abortions – which are widely practiced in that 
country (a detailed discussion of this delicate issue exceeds the scope of this 
thesis) – have harmful but preventable consequences for the population, 
making this subject a “major public health concern” (Dickens and Cook, 2007). 
In addition, health practitioners offering clandestine abortions as well as women 
who interrupt their pregnancy can face significant consequences under the 
Argentinean Criminal Code; punishment for a woman causing her own abortion 
ranges between 1 to 4 years in jail (art.88). 
Patients undergoing prenatal genetic testing will thus clearly need some 
level of counselling, support, and objective information which would be best 
delivered by health care professionals, most likely through the public health 
care system. In the previously mentioned 2004 survey (by the National Centre 
of Medical Genetics) about genetic services in Argentina, there is no mention 
about genetic counselling, nor other kinds of support for prospective parents; 
what follow-on services are necessary to be implemented to help these people? 
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Who should have access to them? Which circumstances would justify such 
access? Certainly one could look to North American and European countries for 
guidance (e.g., where genetic counselling is common), but this would also then 
necessitate consideration of other resource and capacity issues, and in 
particular, whether there are sufficient health professionals trained in medical 
genetics and genetic counselling available in Argentina to meet demand.  
Physicians in Argentina (and even in developed countries) may be 
unprepared for the introduction of genetic tests, or demands from patients for 
counselling, which may lead to serious medical-legal implications (e.g., 
malpractice suits). As Lori Andrews notes, the arrival of genetic tests in medical 
practice has arguably lead to more wrongful birth cases in the US – which could 
potentially also become an issue in Argentina – with resulting pressure on 
physicians to then use more prenatal diagnostic services, increasing the cost to 
the health care system and potentially affecting patient autonomy (Andrews, 
1992). 
In many developed countries, genetic counselling by professionals with 
expertise in clinical genetics plays an important coordinating role in the 
provision of genetic services; the counsellor can help people to understand the 
information provided by tests and plan follow-on care. Yet in the National 
Centre of Medical Genetics survey, there is no mention of genetic counselling 
being available in Argentina. Without such professional support, informed 
choice about undergoing genetic testing – a fundamental norm in contemporary 
medical practice – becomes virtually impossible (Sommer, 2008). 
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In Argentina there are some human and structural resources in medical 
genetics, but major obstacles remain that leave many people with unsatisfied 
health needs. By contrast, wealthy people who can pay for PGT also likely have 
the means of dealing with the consequences of testing. That is, they can 
contract private medical services for treatment (when available) or specialised 
devices that a disabled child may need. And if they decide to terminate a 
pregnancy, they can assume the costs of a safe although clandestine abortion 
(provided either in Argentina or aboard). As Penchaszadeh notes (2009), for 
those (middle-upper class) people accessing private services, “legal restrictions 
don’t seem to apply”. But even when couples accept the task of raising a 
disabled child, there are few specialised public services available in Argentina 
(e.g., educational services to improve social integration), nor is there enough 
government support (e.g., subsidies) for families. In this scenario, deciding not 
to terminate a pregnancy often results in even “more complex decisions to 
assume” (Blancquaert et al., 2002). Given that these issues are shaped by 
social “customs, traditions and values” (Luna, 2006), a comprehensive analysis 
of the socio-cultural environment (appraisal), in combination with detailed 
ethical reflection, becomes all the more important for the HTA process. 
 
PART B - CHALLENGES TO IMPLEMENTING AN ETHICAL HTA 
 Molecular genetic tests have been in use since the 1960s in Argentina, 
primarily for the identification of rare heredity diseases, but also in the context of 
forensics to clarify familial links and to identify children of people who 
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disappeared during the last dictatorship (1976-1983)26. However, as previously 
discussed, the medical application for prenatal diagnosis in the public health 
care and social security system is still quite limited, due largely to the criminal 
status of abortion and political pressure from the Catholic Church. Nor are there 
well developed public policies or regulations governing the use of these 
technologies (Penchaszadeh, 2009; Sommer, 2008). On the other hand, private 
access to such services and technologies is relatively easy (through private 
clinics) and Argentinean professionals employ the same techniques as their 
colleagues in developed countries27. This shows that there is at least some 
degree of acceptability of these technologies by the Argentinean public, and by 
health professionals. 
 As an object of technology evaluation, genetics and its related 
technologies are a very complex matter; as Blancquaert et al. note (2002), 
many questions about HTA seem to be more delicate in the genomics era and a 
considerable number of these issues are narrowly linked to questions about 
appropriateness and acceptance of these new technologies in diverse societies. 
Although some concerns about PGT are shared by other branches of medicine 
(e.g., who will have access to the services and who will pay for them), there are 
other aspects which need to be taken into account when deciding whether to 
introduce them into a health care system. For instance, the use of prenatal 
genetic tests raise ethical and social issues as the right to reproductive 
                                                 
26To this purpose, a national bank of genetic data was created by Argentina’s Congress in 1987 
(National Law no. 23.511) 
27For a detailed list of genetic services and tests already available in Argentina, see for 
example: Primagen Diagnósticos Genéticos available at: 
http://www.primagen.com.ar/diagnosticosprenatales.php   
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autonomy, the subject of respect for private life, the delicate matter of 
confidentiality of genetic information28 and the potential risk of discrimination 
that people, families or even groups can suffer. In addition, predictive tests can 
in some cases lead to the stigmatization of particular patient or population 
groups (Hofmann, 2005 b); they also raise questions about how to address 
diverging personal convictions, values and religious beliefs, all linked to human 
reproduction. In the specific case of Argentina, the lack of regulations or 
guidelines dealing with genetic tests also allows the introduction of predictive 
genetic tests for commercial reasons, which may lack medical validation 
(Sommer, 2008). All these issues pose serious challenges for decision makers. 
Probably one of the most important challenges for an effective HTA in 
Argentina with regards to PGT – or for health services more generally – is the 
fragmentation of the health care system in terms of structure and organisation 
of insurance coverage (discussed in the Introduction of this thesis). This 
disorganisation and fragmentation, along with a scarcity of information (e.g., 
there are no registries about congenital disorders and chromosomal anomalies, 
nor is there any official data about the number of abortions that occur following 
genetic testing)29 mean that it is exceedingly difficult to develop the background 
in which to conduct HTA, to compare services for coverage, or even know 
                                                 
28In Argentina, the Law 421/2000 (ley de Garantías al Patrimonio Genético) for the protection 
against genetic discrimination guarantees and protects the right to dignity, identity and integrity 
of everyone with respect to their genetic heritage. However, this law is only applicable in the 
capital city (Buenos Aires is an autonomous jurisdiction that has its own legislation) thus leaving 
unprotected citizens of the rest of the Nation. In Argentina, there is still a need for specific 
regulation regarding the proper use of human genetic information in biomedical research as well 
as in clinical practice. 
29As Rivera López (2002) notes, the lack of information about the number of abortions 
performed following genetic testing is due to the illegality of such procedures.  
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whether services currently being offered (or envisaged for inclusion in public 
health insurance) are cost-effective and meet (or not) population health needs. 
Even when HTA is conducted, the absence of formal recommendations 
following technology assessments does not allow Argentinean policy makers to 
be fully informed about the range of contextual issues associated with a 
particular technology, and thus they remain unable to “improve the efficiency, 
the equity, the quality and sustainability of the health policies and services”30. 
This situation is made worse by the fact that, in Argentina, the links between the 
scientific and political spheres have been historically quite weak, and policies 
have often been built according to particular interests, which are rarely 
transparent. 
The fact is, however, that Argentina, as with other neighbouring countries 
like Chile and Brazil, is rapidly incorporating new biomedical technologies such 
as molecular genetic tests (primarily into the private health sub-sector) that 
have been developed in industrialised countries (Valencia and Manrique, 2004; 
Zegers-Hochschild, 1999), but without appraising the social or political contexts 
relevant to their introduction. This tendency to adopt health technologies without 
detailed analysis is probably to some extent rooted in a fascination for 
technological progress, and a perception by many people (including policy 
makers and the general public) that access to these technologies is 
                                                 
30Improving “efficiency, equity, quality and sustainability of health policies and services” is the 
goal of the aforementioned IECS. Efficiency is the ability to accomplish what is intended; is the 
most economical way of achieving a task and usually used to control costs. Equity is used as 
synonymous of impartiality (e.g., all citizens have the same rights and obligations). Quality is 
characteristic of excellence. Sustainability is something that may be maintained at a particular 
level, in a balanced situation, avoiding its reduction (e.g., health and social services). 
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synonymous with being at the vanguard of modern medicine, and living in a 
modern society. As Lehoux states (2006), “for several observers, health 
technology…cannot be (irrationally) resisted”, because “technology sounds 
modern… must be about the latest. It is also supposed to be better. But how 
and when do we know that an innovation is better?” To determine that, scientific 
evidence is needed, but also contextual and even historical evidence (e.g., 
about the patient) is required (Battista and Hodge, 1999). The absence of 
contextualised assessments – and integrated appraisals – impedes efforts to 
determine if prenatal genetic tests fit or not into Argentinean society. 
 
Capacity Development for an Ethical HTA 
Given the number of genetic services coming into clinical use, it is 
important to consider, as part of the HTA process, the diverse concerns 
associated with their introduction, particularly with regards to their importance 
for inclusion in the public health care system (discussed in Part A). Facing-up to 
these very real challenges will be a hard task. However, I suggest that progress 
can be made by observing how other countries assess medical (and genetic) 
technologies. This is not to argue that the North American or European models 
of HTA should be copied and directly implanted into the Argentinean context; 
the contextual (social, cultural, political) particularities of each country are 
relevant. Nevertheless, some lessons can be learned from abroad – as has 
been explained in Chapter One, with the example of AETMIS – that can help to 
improve the HTA process in Argentina. 
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 Accepting the current inadequate or insufficient state of HTA in 
Argentina, and in an attempt to map out a preliminary idea of what an ethical 
HTA would look like in this country, I argue that the production of more 
extended and more comprehensive evaluations should be emphasized. As 
Giacomini, Miller, and Browman note, (2003) to assess efficiency, efficacy and 
ethics issues, HTA producers need to have a detailed image about the 
“technology purposes and functions, from a social as well as clinical 
perspective”. 
There have been some recent initiatives in Argentina to evaluate socio-
ethical aspects raised by genetic technologies, albeit still without formal 
integration into HTA processes (Personal communications with Bioethics 
scholars, HTA producers and decision-makers in Argentina, March 2007). The 
aim of such evaluations is to build specific analyses of the ethical, legal, and 
social issues (ELSI) of genetic technologies, as has already been done in other 
countries, most notably in the USA, Canada and in Western Europe. In 
Argentina, some National Universities – such as at the National University of La 
Plata (UNLP) and the National University of Buenos Aires (UBA)31 – have 
begun developing bioethics centres and programs. For example, while the first 
ELSI courses for law and medicine students were taught by invited international 
scholars, it is increasingly local bioethics scholars (many who received training 
                                                 
31The UNESCO Bioethics Chair was established at the University of Buenos Aires (UBA) in 
1994. 
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abroad and participated in other ELSI courses offered in Latin America) who are 
engaged in both research and teaching in Argentina32. 
More recently, several research ethics commissions were created and 
began participating in public and policy discussions about ethics and genetics. 
Thus, for example, the Comision Nacional en Genética Humana (the National 
Commission in Human Genetics) was created by the National Health Ministry 
with the mandate to analyze socio-ethical issues raised by the application of 
genetic technologies33. Another example of such local initiatives is the creation 
of the Observatorio de Bioética in 2002 (functioning at the Facultad 
Latinoamericana de Ciencias Sociales, FLACSO)34 with the aim of contributing 
to the “public and specialized debate” about health matters (FLACSO, 2008).  
Even though these commissions and institutions are not themselves HTA 
agencies, their works can be helpful for HTA producers. The integration of 
ethics with HTA and the introduction of HTA into the policy sphere nonetheless 
remain major challenges (Oliver, Mossialos, and Robinson, 2004), especially in 
developing countries where HTA is still not a priority in government agendas. 
But progress can be made if Argentinean HTA producers begin to build links 
with institutions where technologies are analysed from an ethical and social 
perspective, as is the case of some public universities, ethics commissions and 
                                                 
32The first ELSI course in Genetics, in 1998, was financing by the National Institute of Health 
and Dartmouth College and directed by Prof. Ronald Green; this allowed Prof. M. Graciela de 
Ortúzar to start the first courses on this subjects in Medicine and Law Faculty, in UNLP, CIF, 
followed by several research projects and doctoral theses.  
33Following a recommendation from PAHO (on the base of the data collected by the census 
about genetic services in 2004), this Commission was created by Ministerial Resolution no 149 
in February 2005. 
34Following an initiative of UNESCO, the FLACSO -an intergovernmental organization- was 
created in 1957 with the aim to promote the development of social sciences in Latin America. 
For more information about this organization see: http://www.flacso.org.ar  
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NGO’s. Another possibility is that HTA agencies follow the lead of AETMIS in 
Québec, and incorporate into their staff scholars trained in bioethics in order to 
conduct their own analyses and reports. Such recruitment would be an 
opportunity for HTA staff to build awareness about ethics matters, and for 
bioethicists to recognise the objectives and restrictions of current HTA 
processes (Hofmmann, 2005 a, cited in Lehoux and Williams-Jones, 2007). 
 People trained in bioethics can contribute substantially to the HTA 
processes. Bioethicists can employ several approaches, both theoretical and 
empirical (Lehoux and Williams-Jones, 2007) and may be involved in 
conducting both qualitative and quantitative research to understand and 
measure what people feel or are concerned with, regarding a given technology. 
For instance, such research would be useful in building a better comprehension 
of the experience of those parents undergoing PGT in Argentina. But also by 
referring to ethical principles (e.g., autonomy, beneficence, justice) and 
identifying societal values, an ethical analysis can help to build relevant 
frameworks to better analyse genetic technologies, such as prenatal tests. Such 
research can help to clarify a technology’s social acceptability, appropriateness 
and utility within the Argentinean health care system.  
Expert advice is needed for the development (or at least appearance) of 
sound state policy. As Webster states: “Government is keen to give the 
impression that its decisions are rational, based on the best possible advice 
available” (Webster, 1991). One must clearly be realistic about the other 
political and economic interests at stake for policy makers, but I think we should 
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be positive and recognize that there is place for engaging in better, i.e., more 
ethical, reflection and policy making. Local bioethicists are, I would argue, 
legitimate sources of advice on ethics matters. They could contribute not only to 
the development of more fully informed recommendations (e.g., about 
consequences of adopting or not a given technology, such as PGT), but also to 
the development of greater transparency in the policy arena: HTA evaluations 
and subsequent recommendations can be used to make decisions on rational 
grounds, according to needs and not just according to particular interests or 
preferences. Yet one also needs to recognise – as Webster does – that an 
explicit attention to rational or bioethics-informed policy might also serve implicit 
(and non-transparent) political ends. 
 In addition, to do better HTA in Argentina, public participation is needed, 
and could be encouraged through the implementation of consultative 
mechanisms as have been used by some European agencies, e.g., the 
“Publiforums” implemented by the Swiss Technology Assessment Agency. 
Such integration of citizens panels and other consultative mechanisms (e.g., 
roundtables) that facilitate discussions about the socio-ethical questions raised 
by new technologies (Commissaire à la santé et au bien-être, 2009; Lehoux 
and Williams-Jones, 2007) would go some way towards reflecting the diversity 
of social values, and move beyond strict epidemiological analyses of current 
HTA processes. 
While discussions between different stakeholders groups (e.g., patients 
groups, medical associations, health insurers) should be encouraged in order to 
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clarify the utility of including PGT in Argentinean health care, they are not 
without their challenges. The repeated economic crises and political 
confrontations, the pressure of the Catholic Church, and the subsequent 
interruptions of democracy have been important obstacles for the Argentinean 
population in exercising their rights, and developing their “civic virtues”, 
including the motivation and opportunity to participate in public discussions 
about health and public well being that are so vital in modern democracies 
(Kymlica and Norman, 1999).  
The repression suffered during the last dictatorship, and the constant 
and direct interventions of the Church (e.g., lobbying in deliberative processes, 
specifically for reproductive health matters), have deeply undermined public 
participation. For an important part of the population who grew up under state 
oppression, public discussion of sensitive issues such as abortion for genetic 
reasons can still be a challenge; then, a “double moral standard” exists so that 
people claim to be Catholic but do not follow closely Catholic orthodoxy 
regarding reproduction, contraception and abortion (Luna, 2006).  
The creation of spaces that facilitate and encourage public participation 
is still important; some progress is being made, despite historical reticence. A 
good example is the so called “Argentinean Roundtable”, a public forum 
implemented by the National Ministry of Health, where different sectors of 
society (government, labour associations, scientific societies, the Church, etc.) 
participated in discussions about various health problems and their possible 
solutions (PAHO, 2002). This sort of dialogue, albeit difficult (e.g., because of 
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the political power of the Church) can also be stimulated by those in academia 
– an area that is strongly developed in Argentina – searching for new avenues 
of collaboration with governmental and private institutions. 
While I have here raised important concerns about the effectiveness of 
HTA and ethical analyses in Argentina, I do not mean to underestimate the 
progress that state agencies and private institutions have made in rationally 
assessing health technologies in Argentina. There is no doubt that many have 
conducted pioneering work and made an invaluable contribution to the 
development and management of the health care system. Nonetheless, given 
the significant social inequalities and inequity in access to necessary health 
care that remain in Argentina, and the lack of clear regulations and policy 
concerning genetic tests, it is fair to say that much more work still needs to be 
done. To that end, I argue that HTA in Argentina must engage in a broader or 
contextualized assessment that includes the appraisal of socio-ethical aspects. 
In particular, there is real need to move beyond short technical reports, and to 
formulate pragmatic policy recommendations, as is the case with the AETMIS 
reports produced in Québec. 
 
CONCLUSION 
In modern democratic societies, policy makers play a critical role in 
pursuing the well being of citizens through the design of nuanced and inclusive 
(health) policies, assigning resources where they are most needed, while at the 
same time working with restricted budgets. Since it is impossible to offer all 
possible beneficial services and technologies to all patients, choices must be 
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made and this often implies making a “trade-off between services and 
treatments” (Nauemberg, 2006). In order to be socially accepted, such 
decisions need to be ethically justifiable because allocating resources to a given 
service or technology invariably leads to reduced or limited funding for others 
areas. Distributive justice considerations oblige policy makers to find the best 
way of allocating those resources,35 and thus there is the need to evaluate the 
usefulness of the services, such as genetic tests (Williams-Jones and Burgess, 
2004). Transparency in decisions is needed to build public trust, which requires, 
as has been discussed, making public and explicit the rationales for particular 
decisions.  
Argentina is a nation with some resources in medical genetics: it 
currently has 50 public centres (and many others in the private sub-sector) able 
to deliver the same services that are available in developed and wealthy 
countries. Given the rapid expansion of genetic technologies around the world 
and associated public demand, it would be unreasonable to discontinue their 
provision in Argentina. Nonetheless, a more rational prioritization and planning 
of service provision is essential. For example, it would be important to 
decentralise the current Buenos Aires centred operation of public medical 
genetics facilities, to improve access in the less populated regions of the 
country. For areas where this would not be feasible (e.g., because of 
remoteness and insufficient population), it will be important to develop 
mechanisms to help plan and coordinate service provision, as has been 
                                                 
35Following de Ortúzar (2005), Rawls’ concept of distributive justice can be applied here to 
justify universal obligations to perform certain positive actions to offset inequalities and ensure 
the fair equality of opportunity. 
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developed in countries such as Canada which share the challenges of ensuring 
equitable access to health care across large geographical areas. 
In many areas of policy, Argentina has taken as reference external 
models in order to create and develop its own. The same situation can be 
expected in the case of HTA, and hopefully also the possibility of integrating 
socio-ethical analysis into such processes. In this Chapter, it has been argued 
that the case of PGT has not yet been properly integrated in Argentina; it is a 
contentious subject that needs to be assessed within its own socio-cultural 
context. Therefore, the evaluation of such technology is something that needs 
to be explored, while recognising that its integration into the medical system is a 
delicate matter, strongly shaped by many socio-cultural, economic and political 
factors, and will have repercussions at different levels, implicating a great 
diversity of stakeholders. 
 Primary research is still necessary in Argentina in order to clarify how 
socio-ethical questions should be appraised; then, possible methods to achieve 
such integration can be explored. Here, I have made some suggestions about 
how such integration could occur. Specifically, an important first step should be 
creating awareness on the part of HTA producers and decision makers about 
the importance of conducting comprehensive assessments. Such analyses can 
contribute not only to more efficient technology integration (i.e., to produce the 
desired effect of improved public health), but also to a more efficient and 
equitable organisation of the health care system in Argentina (e.g., to address 
the challenges of understaffing and the chronic under-funding of public genetics 
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facilities). To achieve such awareness, public education and training in ethics 
matters is a good starting point, something that has been recognised as an 
important priority in many developed nations. 
 The academic sphere, and in particular bioethics, can make a valuable 
contribution to Argentinean policy making. Bioethics has been growing in South 
America during the past decade (Luna, 2006; Salles and Bertomeu, 2002), and 
this would be an excellent opportunity to stimulate the integration of ethical 
reflection into HTA and policy making, in order to cope with the local challenges 
posed by genetic technologies. Local bioethics scholars interested in the 
different socio-cultural and ethical issues generated by the introduction of 
reproductive technologies (a prominent focus in Argentina) can genuinely help 
in the identification of concerns and dilemmas. They can, through both 
theoretical and empirical research, help enlighten other aspects that probably 
would not be identified by physicians, economists or politicians, and thus 
improve the production of assessments.  
Using an integrated model of an ethical HTA would provide the basis for 
determining whether or not there is a need for more equal access to PGT in 
Argentina (and its public insurance), in comparison with other important and 
pressing public health needs. Without such an analysis, PGT will remain a hotly 
contested issue for the Argentinean public and a challenge for policy makers; 
and it will leave parents without the professional or social support necessary to 
deal with the complex issues and decisions posed by genetic information. 
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 In 1978, during the International Conference on Primary Health Care of 
Alma Ata (in Kazakhstan, former USSR), it was argued that health technologies 
must be appropriate and relevant to real population needs and affordable for 
the societies (Declaration of Alma Alta, 1978). Given that such appropriateness 
is strongly shaped by particular socio-cultural contexts, comprehensive 
assessments that are broader than traditional HTA processes are required. In 
the particular case of Argentina, those comprehensive analyses are still lacking, 
something that arguably contributes to the diffusion of the most sophisticated 
biomedical technologies through the health care system, but without the 
pertinent evidence that should support and justify such decisions. 
Economic crises and political misrule have resulted in a profound 
institutional decadence and a subsequent impoverishment in the quality of State 
goods in Argentina; the fact is that health care is gradually becoming a privilege 
for which citizens have to pay instead of the fundamental right recognised by 
the National Constitution. This situation has worsened with the application of 
neoliberal policies during the 1990’s which left the most vulnerable members of 
the population almost completely excluded from access to many basic health 
and social services. Furthermore, despite the reforms introduced during the 
1990s, the health care system still needs to be reorganized in a rational way; 
the public provision of different services needs to be significantly improved 
since universal access to health care services – along with access to other 
social services, public education, as well as decent housing, formal 
employment, etc. – are crucial for a healthy population (WHO, 2003). 
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The existence of major inequalities between citizens accessing health 
services in Argentina is a matter of justice that needs political response 
(Daniels, 2001); in a just society, the population’s health needs should be 
prioritized over access to health services that focus on meeting particular 
desires or preferences. Such a possibility simply worsens existing inequalities. 
Many people who might benefit from genetic services and technologies, but 
who cannot currently access them because of economic considerations, would 
have the opportunity if these services were included in public health insurance. 
Yet it should be clear that the suitability of a technology aimed to prevent 
transmittable diseases, such as PGT, will be questionable in a society where its 
application remains socially or religiously controversial. Thus alongside 
considerations of social justice, i.e., equity in access, it is important to also 
attend to issues of reproductive autonomy and the religious influence on legal 
restrictions, when evaluating the importance of genetic services and prenatal 
testing for coverage in public health insurance. 
In a country with tremendous socio-economic inequalities, and where the 
provision of many basic services still need to be improved, introducing 
contentious technologies such as PGT into public health insurance coverage 
may seem foolish (Penchaszadeh, 2009). Yet, publicly funding PGT could help 
to reduce significant inequalities in health and access to health care, thus 
favouring the situation of the most vulnerable members of the population. Given 
the diversity of concerns raised by the application of PGT, the answer will not 
be easy. What is clear is that the health of some populations in less developed 
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countries such as Argentina will not be improved given the impossibility of 
accessing new tests and new drugs to treat illnesses with genetic origins, 
especially congenital defects (de Ortúzar, 2004).  
Removing obstacles to universal access to health care services is 
critical. For that to occur innovative and more inclusive health policies are 
urgently required in Argentina; this poses challenges for policy makers who 
need good evidence to make decisions on rational grounds. Part of the solution 
to clarifying the pertinence of contentious technologies, such as PGT, can be 
found in the production of comprehensive ethical HTA. That is, a global 
appraisal of the context needs to be performed in order to enlighten policy 
recommendations about the reality in which a new technology, such as PGT, is 
going to be applied (Johri and Lehoux, 2003). Issues regarding the accuracy of 
PGT, its potential utility and benefits for the Argentinean socio-cultural context, 
and its governance must all be analysed before deciding on its implementation. 
Introducing PGT without addressing these questions will only contribute to 
further increasing the already dramatic inequalities that exist between fellow 
citizens. Integrating ethics and HTA processes can, I have argued, result in an 
effective tool – and even a method in itself – for addressing delicate issues 
raised by the introduction of medical technologies and other health innovations. 
Working towards such integration is essential. 
The principal pitfalls for the production of HTA in Argentina – namely 
misunderstanding of decision makers about the roll of HTA in the organisation 
and management of the health care systems, and the absence of specialised 
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staff in the matter (PAHO,1998) – can be overcome. However the current 
situation is still far from perfect: although decision makers are becoming aware 
about the relevance of HTA for health care systems and there are currently 
trained people in the field, substantial efforts are still required to implement 
better and more ethical HTA. More interaction between these two 
multidisciplinary fields of study, that is, HTA and Bioethics, is needed. Local 
bioethicists are able to give useful advice on critical issues, such as better 
resource management, health promotion and ethical matters in research 
(PAHO, 2004). Specifically, Argentinean bioethics scholars can and should play 
an active role in HTA processes. Working in collaboration with HTA producers 
can genuinely contribute to the policy sphere in Argentina, by making explicit 
the socio-ethical questions that arise from the application of PGT in order to 
design coherent recommendations for nuanced and realistic health and public 
policies that can, hopefully, be implemented in more transparent fashion. 
It is important to emphasise that the lack of comprehensive analyses is a 
major obstacle for the production of punctual and pragmatic recommendations 
(Blanquaert, 2006) that are so vital to the design of realistic health policies. For 
that, I suggest, that more empirical research in the social sciences (sociology, 
economics, etc.) and qualitative studies are necessary in Argentina in order to 
collect local and pertinent data to facilitate the production of contextualised 
assessments. In addition, much more public education in ethics matters is 
needed in Argentina, especially ethics related to genetics, something that would 
benefit patients, health professionals and policy makers (Consultación Pública 
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para un Sistema Nacional de Ética y Derechos Humanos en Investigación 
Biomédica, 2006). 
At present, physicians and other health professionals do not receive 
“formal courses in clinical genetics, genetic counselling and/or public health 
genetics” as part of their medical curricula (Penchaszadeh, 2009). Remedying 
this situation, and incorporating ethics into the medical curricula, would go some 
way to ensuring that future health professionals are able to offer medical 
genetic services in a manner that is both clinically appropriate and sensitive to 
patient needs. Finally, policy makers have the duty to protect public health and 
welfare, thus they need to be conscious about the implications of deciding to 
allocate resource towards expensive and controversial technologies that may 
not be “in keeping with the local culture” (Declaration of Alma Alta, 1978). 
In South America, Argentina is one of the most advanced nations in the 
fields of genetics: the country counts some of the most prestigious medical 
facilities, such as the aforementioned Garraham hospital, and numerous public 
and private centres providing genetic services and testing. Planning and 
coordination between these facilities would be an important means of improving 
access to genetic services and prenatal testing. The current reality is that in 
Argentina, the use of genetic technologies is expanding despite the lack of 
regulations and public policies, and this situation is unlikely to change in the 
near future. Nevertheless, there are some government initiatives to improve 
access to genetic services and related technologies, thus it is all the more 
important that these genetic services be available to all in need. Equitable 
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access, accurate information and appropriate support are critical to facilitate 
prospective parents to make informed and autonomous decisions. 
Hopefully, the case of PGT presented in this work has helped illustrate 
the fact that new technologies cannot be taken for granted; and maybe some 
lessons can be learned for the future. I have argued that unfair and unethical 
situations can be diminished or even prevented if decisions are taken on the 
basis of more comprehensive HTA analyses, performed at a local level. For that 
to be accomplished, it would be necessary to encourage the production of 
technology assessments at the provincial or regional level in Argentina, e.g., by 
dividing the country into regions to produce local evaluations following a 
national strategy (including defined assessment priorities, common guidelines 
and evaluation methods), as has already been done in other jurisdictions. The 
possibility of creating an Argentinean HTA Network should also be explored. 
For many reasons which have been explained in this thesis, Argentina 
represents a fertile ground for the production of HTA, and the country has a real 
possibility to play an important role in the promotion of ethical HTA and its 
relevance for policy in South America. However the situation of vulnerability in 
which many people live in developing nations must be taken into account; the 
conditions required for the real exercise of a deliberative democracy (e.g., 
public discussions on health subjects) are currently far from perfect in 
Argentina. Education is required to create these conditions (Sommer, 2008) and 
to have informed people deliberating in fair conditions. As noted by Traynor and 
colleagues, “inadequate information is the most often cited impediment for 
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deliberations” (Traynor, Adonis, and Gil, 2007). On this aspect, there is still 
much need for bioethics research in Argentina and other neighbouring 
countries. 
In 2010, Argentina will celebrate 200 years of autonomy from Spain; 
however, by that time, the country will have had only 26 years of continued and 
genuine democracy. Hopefully, as democracy continuous over time, civil society 
will take part more fully in open and inclusive deliberations about subjects such 
as health care, allowing Argentineans to reach at least a minimal consensus 
about sensitive matters such as PGT. Although it is obvious that many other 
actions would need to be implemented to solve the broader socio-political and 
economic challenges facing Argentinean society, I suggest that integrating 
ethics with HTA can be part of the solution. By giving policy makers some of the 
tools needed to reorganise and rationalise the country’s intricate and overly 
complex health care system, an ethical HTA can help ensure safer and more 
equitable access to services and technologies such as PGT. 
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